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ABSTRACT	
The	 heterogeneous	 nuclear	 ribonucleoproteins	 (hnRNPs)	 form	 a	 large	 family	 of	 RNA-
binding	proteins	(RBPs)	that	exert	numerous	functions	in	RNA	metabolism.	For	example,	
soluble	 hnRNPs	 bind	 to	 RNAs	 to	 mediate	 their	 maturation,	 processing,	 and	 shuttling	
from	 the	 nuclear	 compartment	 to	 the	 cytoplasm.	 Additionally,	 hnRNPs	might	 interact	
with	chromatin	to	regulate	the	transcription	and	the	post-transcriptional	modification	of	
nascent	transcripts.		
RALY	 is	a	member	of	 the	hnRNP	 family	 that	binds	poly-U	 rich	elements	within	 several	
RNAs	 and	 regulates	 the	 expression	 of	 specific	 transcripts.	 RALY	 is	 upregulated	 in	
different	 types	 of	 cancer	 and	 its	 downregulation	 has	 been	 shown	 to	 impair	 cell	
proliferation.	 In	my	PhD	project,	 I	 characterized	RALY	 to	 interact	with	 transcriptionally	
active	chromatin	in	a	transcription-dependent	manner	and	to	cause	a	global	decrease	of	
RNA	 Polymerase	 II	 (RNAPII)-mediated	 transcription	 when	 downregulated,	 without	
affecting	 RNAPII	 elongation	 rate.	 Through	microarray	 analysis	 of	 RALY-downregulated	
HeLa	cells,	I	detected	an	altered	expression	of	numerous	genes	involved	in	transcription	
promotion	and	cell	cycle	regulation,	 including	the	E2F	transcription	factors	family.	Due	
to	its	relevant	role	in	regulating	the	cell	cycle,	I	focused	on	the	proliferation-promoting	
factor	E2F1.	 I	demonstrated	that	the	stability	of	E2F1	mRNA	 is	 reduced	 in	cells	 lacking	
RALY	expression,	with	a	resulting	reduction	of	E2F1	protein	levels.	As	a	consequence	of	
RALY	knock-out,	HeLa	cells	present	a	slower	cell	proliferation	compared	to	control	cells.	
Finally,	 by	 crossing	 the	 list	 of	 RALY	 targets	 with	 the	 list	 of	 genes	 affected	 by	 RALY	
downregulation,	 I	 propose	 a	 positive	 role	 of	 RALY	 in	 regulating	 the	 fate	 of	 specific	
transcripts.		
Taken	together,	my	results	highlight	the	importance	of	RALY	expression	for	transcription	
and	cell	proliferation.	
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1. Introduction	
The	phenomenon	of	 heredity	 and	 the	 capacity	 of	 organisms	 to	 reproduce	 themselves	
are	 central	 to	 the	 definition	 of	 life:	 it	 makes	 living	 beings	 distinguishable	 from	 other	
natural	 systems.	 Every	 cell	 possesses	 a	 genome,	 the	 “hard	 drive”	 harboring	 the	
information	 that	will	define	 the	biological	and	phenotypical	 traits	of	 the	organism	and	
that	 will	 be	 passed	 to	 the	 offspring	 to	 allow	 the	 pursuance	 of	 the	 species.	 The	
information	is	stored	in	the	form	of	DNA,	but	to	be	allowed	to	free	all	of	its	potential,	it	
has	 to	 be	 brought	 into	 the	 form	 of	 proteins	 and	 other	molecules	 that	 will	 allow	 the	
biological	machine	 to	work	 correctly.	 In	 between	 the	 path	 from	DNA	 to	 proteins,	 the	
genetic	 information	passes	through	the	intermediary	form	of	RNA,	that	will	be	used	as	
template	 to	 direct	 the	 synthesis	 of	 proteins.	 Proteins	will	 ultimately	 administrate	 the	
information	 held	 by	 DNA	 and	 RNA,	 and	 the	 balance	 between	 different	 classes	 of	
proteins	will	 determine	 the	behavior	 of	 the	 entire	 cell,	 possibly	 leading	 it	 to	 adapt	 to	
different	 environments,	 to	 proliferate	 and	 even	 to	 die	 to	 preserve	 the	 fitness	 of	 the	
entire	 organism.	 The	 information	 flow	 from	DNA	 to	 proteins	 holds	 the	 name	 of	 gene	
expression.	Most	of	the	genes	of	higher	eukaryotes	are	composed	by	coding-	and	non-
coding-	 regions,	 namely	 exons	 and	 introns,	 respectively.	 Only	 exons	 contain	 the	
information	 to	 give	 birth	 to	 the	 final	 protein,	 while	 introns	 will	 be	 lost	 during	 the	
processing	of	RNA.		
Prior	 to	 the	 genome	 sequencing	 era,	 the	 idea	 that	 the	 complexity	 of	 organisms	 was	
directly	proportional	 to	 the	number	of	genes	was	 fairly	accepted.	Nowadays	we	know	
that	a	high	number	of	genes	does	not	always	correlate	with	complexity.	In	fact,	it	is	the	
regulation	of	gene	expression	in	space	and	time	to	be	determinant	for	the	formation	of	
complex	organisms.	 In	addition,	 to	make	the	system	even	more	articulated,	numerous	
genes	 will	 not	 end	 up	 in	 a	 protein	 form,	 giving	 rise	 instead	 to	 regulatory	 non-coding	
RNAs,	and	single	genes	can	give	rise	to	many	different	proteins	through	the	process	of	
alternative	splicing.		
There	are	multiple	ranks	of	gene	expression	control,	which	can	be	grouped	depending	
on	the	form	of	the	information	they	target.	 In	the	first	place,	 it	 is	the	activation	or	de-
activation	 of	 a	 single	 gene	 to	 determine	 the	 beginning	 of	 the	 information	 flow.	 This	
ON/OFF	switch	is	mainly	exerted	by	factors	that	bind	to	the	regulatory	DNA	sequences,	
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in	 particular	 to	 promoters,	 which	 are	 located	 upstream	 the	 sequence	 of	 the	 gene.	
However,	a	consistent	part	of	gene	expression	control	occurs	at	the	level	of	RNA,	during	
and	after	its	synthesis.	
1.1	 A	journey	through	RNA	transcription	
The	 process	 through	 which	 the	 information	 is	 moved	 from	 DNA	 to	 RNA	 is	 named	
transcription.	It	is	a	very	complex	procedure	that	involves	numerous	proteins,	identified	
as	 the	 transcriptional	machinery,	 and	 trans-acting	 factors	 that	 co-operate	with	 it	 and	
interact	with	 the	newly	 synthesized	RNA	 to	ensure	 its	 correct	processing	 1–4.	During	a	
transcriptional	 event,	 a	 long	 sequence	 of	 DNA	 will	 be	 copied	 into	 a	 complementary	
molecule	of	RNA,	termed	pre-messenger	RNA	(pre-mRNA).		
The	 leading	 actor	 of	 transcription	 is	 the	 RNA	 Polymerase	 (RNAP)	 holoenzyme,	 the	
protein	complex	responsible	for	the	reading	of	the	DNA	sequence	and	for	the	assembly	
of	 the	complementary	RNA	copy.	Eukaryotes	present	three	different	RNA	Polymerases	
(I-III),	 which	 are	 responsible	 for	 the	 transcription	 of	 determined	 sets	 of	 RNAs.	 In	
particular,	the	complex	responsible	for	the	synthesis	of	protein-coding	pre-mRNAs,	but	
also	of	determined	non-coding	RNAs,	is	RNA	Polymerase	II	(RNAPII).	In	human,	RNAPII	is	
composed	 by	 12	 subunits	 (RPB1-12),	 of	 which	 RPB1	 is	 the	 largest	 and	 most	
characterized.	RPB1	 forms	 the	DNA	binding	domain	of	RNAPII	and	contains	a	carboxy-
terminal	domain	 (CTD),	composed	by	up	to	52	heptapeptide	repeats	 (Y1-S2-P3-T4-S5-P6-
S7),	 that	will	be	chemically	modified	during	transcription	to	regulate	the	activity	of	the	
whole	 holoenzyme	 and	 to	 recall	 trans-acting	 factors	 involved	 in	 the	 co-transcriptional	
processing	of	nascent	RNAs	2,5–13.		
The	transcriptional	activity	of	RNAPII	can	be	divided	into	three	main	phases:	recruitment	
of	 the	 holoenzyme	on	 the	 regulatory	 sequence	of	 the	 gene,	 initiation	of	 transcription	
and	 productive	 elongation,	 and	 termination	 14.	 After	 20-60	 nucleotides	 from	 the	
transcription	 start	 site,	 RNAPII	 is	 driven	 in	 a	 paused	 condition	 by	 two	 proteins:	 the	
negative	 elongation	 factor	 (NELF)	 and	 the	 DRB-sensitivity	 inducing	 factor	 (DSIF)	 15–17.	
During	 this	 pausing,	 the	 newly	 synthesized	 RNA	 undergoes	 capping,	 one	 of	 the	 first	
modifications	 on	 the	 way	 to	 become	 mature,	 and	 the	 CTD	 of	 RNAPII	 is	 post-
translationally	modified	 to	ensure	a	correct	productive	elongation	 17,18.	The	pausing	of	
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RNAPII	 at	 promoter-proximal	 regions	 works	 as	 a	 control	 step	 for	 gene	 expression.	 In	
fact,	at	this	stage,	the	fate	of	the	RNA	can	be	positively	or	negatively	influenced	17.	The	
phosphorylation	 of	 the	 pausing	 inducing	 factors	 and	 of	 the	 CTD	 itself,	 enables	 the	
RNAPII	 to	 resume	 transcription	 19.	 In	 particular,	 the	 driving	modification	 for	 switching	
from	 the	 paused	 state	 to	 productive	 transcription	 is	 the	 phosphorylation	 of	 serine	
residues	 2	 (pS2)	 of	 the	 CTD	 heptapeptide	 20.	 This	 modification	 is	 performed	 by	 the	
Positive	Transcription	Elongation	Factor	b	 (P-TEFb),	a	complex	composed	by	 the	Cyclin	
Dependent	Kinase	9	(CDK9)	and	one	of	the	Cyclins	T	(CCNT1,	CCNT2a,	CCNT2b)	or	Cyclin	
K.	In	humans,	about	80%	of	the	cellular	P-TEFb	is	composed	by	CDK9	bound	to	CCNT1.	P-
TEFb	can	act	either	alone	or	as	part	of	different	complexes	21–23.		
After	 being	 released	 from	 the	 pause,	 RNAPII	 proceeds	 through	 elongation	 and	 finally	
arrives	 to	 termination,	when	the	pre-mRNA	will	detach	 from	the	holoenzyme	catalytic	
pocket.	As	the	initiation	phase,	also	the	elongation	part	of	the	RNAPII	activity	 is	tightly	
regulated.	 In	fact,	RNA	processing	takes	place	in	a	co-	and	post-transcriptional	manner	
and	 is	 tightly	 dependent	 on	 the	 elongation	 conditions	 of	 RNAPII.	 The	 pre-mRNA	
macromolecule	will	undergo	to	a	series	of	modifications,	namely	RNA	capping,	splicing,	
A-to-I	editing,	3’-end	processing,	addition	of	chemical	groups	and	poly-adenylation,	that	
will	ultimately	transform	the	pre-mRNA	into	a	messenger	RNA	(mRNA)	molecule	8–13.		
In	 particular,	 the	 splicing	 of	 pre-mRNAs,	 the	 process	 during	which	 introns	 are	 cut	 out	
from	 the	 pre-mRNA	 and	 exons	 are	 welded	 together,	 is	 highly	 influenced	 by	 RNAPII	
elongation	speed.	Exons	and	introns	are	recognized	by	splicing	factors	thanks	to	specific	
and	conserved	sequences	at	their	extremities.	Depending	on	their	sequences,	the	splice	
sites	 can	 strongly	 or	 weakly	 attract	 splicing	 factors,	 determining	 the	 inclusion	 or	
exclusion	of	the	exon	in	the	final	mRNA.	Different	studies	support	the	so-called	“kinetic	
model”,	 where	 a	 slower	 elongation	 promotes	 exon	 inclusion,	 favoring	 the	 binding	 of	
splicing	factors	to	weak	splice	sites,	which	would	have	been	lost	 in	favor	of	afterwards	
synthesized	 strong	 splice	 sites	 in	 a	 condition	 of	 faster	 RNAPII	 elongation.	 The	 slower	
RNAPII	opens	a	wider	“window	of	opportunity”	for	splicing	factors	to	bind	weak	splice	
sites	24–28.		
By	 including	 or	 skipping	 exons	 during	 splicing,	 a	 single	 genetic	 locus	 can	 give	 birth	 to	
multiple	mRNAs,	which	will	code	for	different	isoforms	of	the	same	protein.	This	puzzle-
like	 process	 holds	 the	 name	of	 alternative	 splicing,	 and	 the	majority	 (>95%)	 of	 higher	
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eukaryotes	genes	is	alternatively	spliced	3.	Both	constitutive	and	alternative	splicing	are	
performed	 co-transcriptionally	 by	 the	 symphonic	 activity	 of	 numerous	 RBPs	 and	
ribonucleoprotein	particles	 (RNP)	assembled	 into	a	huge	complex	named	spliceosome,	
which	 has	 the	 task	 to	 remove	 the	 introns	 from	 the	 pre-mRNA	 3,26,29,30.	 In	 higher	
eukaryotes,	 introns	 can	 be	 distinguished	 in	 U2-	 and	 U12-type	 depending	 on	 specific	
consensus	 sequences,	 and	 they	 are	 specifically	 spliced	 by	 two	 different	 spliceosomes,	
the	 major	 or	 the	 minor	 spliceosome,	 respectively.	 These	 two	 complexes	 are	
compositionally	 different	 but	 functionally	 analogous.	 U12-type	 introns	 are	 a	 minor	
subgroup	 of	 introns	 and	 only	 account	 for	 less	 than	 0.5%	 of	 all	 introns	 in	 any	 given	
genome	29,31.	Both	the	spliceosomes	are	very	dynamic	RNP	complexes,	constituted	by	a	
fundamental	building	block	of	up	to		five	small-nuclear	RNAs	(snRNAs),	present	as	small-
nuclear	 RNPs	 (snRNPs),	 and	 over	 300	 proteins.	 Most	 of	 the	 interactions	 and	 the	
reactions	performed	by	the	spliceosomes	on	RNA	are	the	result	of	an	intricate	puzzle	of	
bindings,	associations	and	 tertiary	 structures	made	by	quickly	exchanging	components	
of	these	machineries,	and	of	the	contribution	of	numerous	trans-acting	RBPs	3.	
	
The	 termination	 of	 transcription	 occurs	 differently	 between	 the	 mammalian	 RNA-
Polymerases,	with	 the	 RNAPII	mechanism	being	 the	most	 complicate.	 Interestingly,	 in	
mammals,	transcription	termination	can	occur	from	a	few	bases	till	kilobases	after	the	
poly-adenylation	site	32.	Transcript	termination	 is	 intimately	connected	with	the	3’-end	
processing	of	 the	pre-mRNA,	and	 to	be	 terminated,	a	protein-coding	pre-mRNA	needs	
an	 intact	 poly-adenylation	 site	 33,34.	 Defects	 in	 the	 termination	 process	 can	 cause	 the	
production	 of	 aberrant	 RNAs	 and	 can	 affect	 the	 transcription	 of	 downstream	 genes,	
possibly	 leading	 to	 the	 unwanted	 transcription	 of	 anti-sense	 RNAs	 and	 determining	 a	
shortage	 in	 the	 free	 RNAPII	 available	 for	 new	 rounds	 of	 transcription.	 Nevertheless,	
defective	 transcripts	 are	 usually	 degraded	 by	 different	 nucleases,	 however	 eventually	
generating	unbalances	in	protein	levels	given	the	lower	amount	of	correctly	terminated	
RNAs.	 Notably,	 given	 the	wide	 involvement	 of	 RNAs	 in	 the	 control	 of	 various	 cellular	
processes,	RNA	degradation	 is	highly	efficient	 and	 incredibly	 fast,	 so	not	 to	 leave	 free	
RNA	fragments	floating	inside	the	cell	35.	
The	newly	formed	mRNA	molecule	will	be	used	as	blueprint	by	ribosomes	to	synthesize	
proteins	in	the	process	of	translation.	Messenger	RNAs	that	are	not	properly	processed	
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will	 be	 considered	 as	 non	 functional	 by	 the	 cellular	 machinery	 and	 successively	
degraded.		
	
The	 maturation	 steps	 bringing	 the	 pre-mRNA	 to	 mRNA,	 namely	 RNA	 processing	 and	
maturation,	 and	 the	 regulation	 of	mRNA	 stability,	 localization,	 and	 translational	 state	
undergo	the	name	of	post-transcriptional	gene	regulation	(PTGR)	36.	Phenomena	tuning	
and	 affecting	 PTGR	will	 ultimately	 determine	 the	 amount	 of	 every	 protein	 inside	 the	
cells.	A	representation	of	the	genetic	information	flow	is	depicted	in	Fig.	1.	
	
Figure	1.	Schematic	representation	of	the	genetic	information	flow.	
1.2	 RNA	Binding	Proteins	
The	proteins	responsible	for	the	maturation	and	the	homeostasis	of	RNA	are	collectively	
known	as	RNA-binding	proteins	(RBP).	In	humans,	a	recent	census	identified	1542	RBPs,	
all	of	which	are	 involved	either	directly	or	 indirectly	 in	protein	synthesis	and	therefore	
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participate	 to	 PTGR	 36.	 Interestingly,	 almost	 all	 the	 identified	 RBPs	 had	 no	 tissue-
specificity	and	the	mRNAs	coding	for	RBPs	constituted	more	than	the	20%	of	the	total	
mRNAs	of	the	cells,	altogether	highlighting	the	importance	of	RBPs	in	cellular	physiology.	
Inside	 the	 cells,	 RBPs	 assemble	 with	 RNAs	 into	 dynamic	 RNPs	 that	 mature,	 process,	
regulate	 the	 translation	and	 transport	of	 the	 transcripts	 (Fig.	 2).	 In	addition,	RBPs	and	
RNPs	 operate	 as	 RNA	 chaperones	 helping	 the	 transcripts	 to	 assume	 their	 correct	
secondary	 structure,	 but	 also	 preventing	 the	 aggregation,	 misfolding	 and	 incomplete	
processing	of	RNAs.	As	a	consequence,	the	abundance	of	RBPs	differentially	affects	RNA	
regulation,	determining	the	abundance	of	proteins	and	specific	isoforms	inside	the	cells	
and	therefore	indirectly	influencing	cellular	processes	36–38.		
	
Figure	2.	Summary	of	the	main	functions	of	RNA-binding	proteins.	
From	the	structural	point	of	view,	RBPs	are	constituted	by	a	 limited	number	of	amino	
acidic	modules,	 and	 the	 incredibly	 large	 substrate	 diversity	 recognition	 is	 achieved	 by	
the	 different	 arrangement	 of	 these	 recurrent	 building	 blocks	 in	 their	 RNA-binding	
domain	(RBD)	(Fig.	3).	The	modularity	of	the	RBD	is	the	key	to	both	binding	specificity	
and	target	versatility	39,40.	In	fact,	these	singular	elements	usually	weakly	recognize	short	
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stretches	 of	 nucleotides	 and	 the	 juxtaposition	 of	multiple	 different	 or	 equal	modules	
allows	 the	 fine	 tuning	 of	 both	 target	 binding	 strength	 and	 specificity.	 More	modules	
permit	to	the	protein	to	specifically	recognize	longer	nucleotide	stretches	or	sequences	
that	 are	 separated	 by	 an	 intervening	 nucleotide	 tract,	 but	 also	 target	 sequences	
localized	on	two	different	RNAs.	The	length	and	structure	of	the	linker	region	between	
two	modules	also	play	a	crucial	role	in	the	recognition	capability	of	the	RBD	39.	An	RNA-
binding	protein	will	bind	to	its	target	RNA	when	a	determined	series	of	parameters,	such	
as	 sequence,	 structure	 of	 the	 RNA	 and	 interactions	 with	 other	 proteins	 are	 satisfied.	
Depending	on	the	RBD,	an	RBP	can	recognize	single-	and/or	double-stranded	RNA	39,41.	
	
Figure	 3.	 Representative	 examples	 of	 the	 variability	 in	 the	 organization	 of	 recurrent	 structural	
modules	in	some	of	the	most	characterized	RBPs.	The	specific	disposition	of	the	modules	allows	the	
RBPs	to	perform	specific	functions.	RRM=RNA-Recognition	Motif,	by	far	the	most	characterized	RNA-
binding	protein	module.	KH=K-homology	domain,	 able	 to	bind	both	 single-stranded	RNA	and	DNA.	
dsRBD=double-stranded	 RNA-binding	 domain,	 a	 sequence-independent	 dsRNA-binding	 module.	
ZnF=RNA	binding	 zinc-finger	domain.	 Enzymatic	domains	and	 less	 common	 functional	modules	are	
also	shown.	PABP=poly(A)-binding	protein.	PAZ=Piwi	Argonaut	and	Zwille	domain.	Picture	taken	and	
modified	from	Lunde,	Moore	and	Varani,	2007	39.	
In	 addition,	multiple	 different	 RBPs	 are	 simultaneously	 bound	 to	 every	 RNA,	 allowing	
RNPs	 to	 perform	 an	 even	 more	 various,	 specifically	 and	 sensitively	 tuned	 array	 of	
functions.	 A	 specific	 RNA-binding	 protein	 in	 fact,	 can	 have	 different	 targets	 and	
functions	 depending	 on	 the	 other	 RBPs	 interacting	 with	 it	 and	 with	 the	 target	 RNA.	
Often,	 RBPs	 create	 homodimers	 to	 interact	 with	 their	 targets,	 performing	 different	
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functions	 compared	 to	 the	 single	 RNA-binding	 protein.	 Virtually	 all	 the	 interactions	
ultimately	result	in	the	post-transcriptional	regulation	of	gene	expression	39,42.		
The	most	common	and	characterized	RBD	is	the	RNA-recognition	motif	 (RRM).	Around	
ten	 thousand	 RRMs	 have	 been	 described,	 and,	 interestingly,	 around	 0.5-1%	 of	 the	
human	genes	contain	the	sequence	coding	for	an	RRM,	often	in	multiple	copies	39,43,44.	
RRMs	are	usually	80-90	amino	acids	long,	containing	two	conserved	sequences	of	eight	
and	 six	 amino-acids,	 respectively	 called	 RNP1	 and	 RNP2,	 and	 recognize	 between	 four	
and	eight	nucleotides	long	sequences.	Given	this	short	sequence	specificity,	also	in	this	
case,	multiple	RRMs	are	often	present	in	the	same	protein	39,45,46.	RRMs	usually	adopt	a	
typical	β1α1β2β3α2β4	topology	that	forms	a	four-stranded	β-sheet	packed	against	two	
α-helices.	Interestingly,	beyond	protein-RNA	interactions,	RRMs	have	been	described	to	
mediate	 also	 protein-protein	 interactions,	 further	 enlarging	 the	 capabilities	 of	 RNA-
binding	proteins	possessing	an	RRM	39,47.		
RNA-binding	 proteins	 are	 grouped	 into	 different	 families,	 one	 of	 which	 is	 the	
heterogeneous	nuclear	ribonucleoprotein	(hnRNP)	family.	
1.3	 The	hnRNP	family	
Historically,	 the	 term	 hnRNP	 was	 coined	 to	 indicate	 all	 the	 proteins	 interacting	 with	
nuclear	 high	 molecular	 weight	 RNA	 (the	 pre-mRNA,	 indicated	 also	 as	 heterogeneous	
nuclear	RNA)	synthesized	by	RNAPII	48.	Later	on,	the	definition	evolved,	indicating	all	the	
proteins	 that	 could	 be	 cross-linked	 to	 hnRNA	 with	 UV	 radiation	 in	 vivo.	 Given	 this	
definition,	it	is	no	surprise	to	find	consistent	structural	diversity	among	the	members	of	
the	 hnRNP	 family	 49.	 hnRNP	 A1,	 A2/B1,	 B2,	 C1	 and	 C2	were	 the	 first	 to	 be	 identified	
given	 their	 abundance	 and	 somewhat	 constitutive	 association	 to	 hnRNAs,	 and	 were	
therefore	 called	 the	 hnRNP	 “core”	 or	major	 hnRNPs.	Minor	 hnRNPs	 are	 the	 ones	 not	
stably	 associated	 to	 pre-mRNAs	 37,48,50.	 To	 date,	 more	 than	 30	 hnRNPs	 have	 been	
identified	 and	 described	 to	 participate	 to	 different	 steps	 of	 RNA	 processing	 and	
metabolism,	 such	 as	 splicing,	 nucleo-cytoplasmic	 shuttling,	 RNA	 transport	 and	 mRNA	
stability	 maintenance,	 but	 also	 to	 other	 cellular	 processes	 (Fig.	 4)	 51,52.	 From	 the	
structural	point	of	view,	hnRNPs	are	characterized	by	the	presence	of	single	or	multiple	
RBD	modules,	which	confer	different	sequence	specificities,	and	of	at	 least	an	auxiliary	
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domain	determining	 the	 localization	or	mediating	protein-protein	 interactions	 51,53–57	 .	
	
Figure	4.	Schematic	representation	of	the	members	of	the	hnRNP	family.	Modified	from	Han	et	al.	58.	
RRM=RNA	Recognition	Motif,	aRMM=atypical	RNA	Recognition	Motif,	KH=K	Homology	domain,	Gly-
Rich=Glycine	Rich.	
After	 the	 synthesis	by	RNAPII,	every	 transcript	will	be	associated	 to	a	 specific	array	of	
hnRNP	 partners,	 as	 well	 as	 other	 RBPs,	 that	 will	 altogether	 form	 the	 messenger-
ribonucleoprotein	particle	(mRNP).	The	specificity	of	the	bound	RBPs	will	 influence	the	
processing	of	the	future	mRNA,	resulting	in	an	“mRNP	code”	that	will	determine	the	fate	
of	the	mRNA.	The	hnRNPs	associated	with	a	single	RNA	exchange	very	quickly,	making	
this	 code	 a	 very	 dynamic	 parameter	 regulating	 the	 phases	 of	 mRNA	 processing.	
Interestingly,	 core	 hnRNPs	 (such	 as	 hnRNP-A1	 and	 -C1)	 are	 present	 in	 the	 nucleus	 at	
concentrations	 similar	 to	 fundamental	 nuclear	 components	 as	 histones,	 and	 in	 vast	
excess	 over	 their	 respective	 binding	 sites.	 This	 abundance	 allows	 these	 hnRNPs	 to	
establish	also	sequence	non-specific	 interactions	with	 transcripts,	enlarging	 their	array	
of	functions	59,60.	
1.3.1	hnRNPs	in	transcription	and	RNA	processing	
A	 function	 in	 constitutive	 and/or	 alternative	 splicing	 has	 been	 demonstrated	 or	
proposed	for	more	than	half	of	the	major	hnRNPs.		
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HnRNP-A1/A2	possess	two	RRMs	at	the	N-terminus	and	a	Glycine-rich	region	(RGG)	at	
the	C-terminus,	which	also	contains	a	nuclear-cytoplasmic	shuttling	domain.	They	can	
both	repress	and/or	promote	splicing	events	ultimately	determining	exon	skipping	or	
inclusion.	Moreover,	they	were	described	to	mediate	the	transport	and	the	stability	
of	 specific	 mRNAs,	 and	 also	 to	 regulate	 gene	 expression	 by	 influencing	 RNAPII	
elongation	49,61–65.	
HnRNP-C1/C2	 (hnRNP-C)	 are	 two	 strictly	 nuclear	 proteins	 presenting	 a	 N-terminal	
RRM,	 followed	 by	 a	 nuclear	 retention	 signal	 and	 a	 basic-leucine	 zipper-like	 motif	
(bZLM)	typical	of	DNA-binding	proteins.	Interestingly,	is	the	basic	amino	acidic	region	
preceding	 the	 bZLM	 to	 provide	 the	 high	 affinity	 for	 RNA,	 while	 the	 RRM	 plays	 a	
minimal	role	in	determining	the	binding	to	RNA	49,66,67.	HnRNP-C	was	detected	to	bind	
poly-U	tracts	in	all	nascent	transcripts	and	to	be	involved	in	splicing	and	in	regulating	
the	 stability	 of	 specific	 mRNAs.	 Interestingly,	 hnRNP-C	 was	 shown	 to	 exert	 a	
protective	role	in	masking	cryptic	3’-splice	sites	into	repeated	ALU	sequences	present	
in	pre-mRNAs,	preventing	their	 recognition	by	the	spliceosome	and	their	successive	
inclusion	into	mature	transcripts	49,68.	
HnRNP-U,	 also	 known	 as	 Scaffold	 Attachment	 Factor	 A	 (SAF-A),	 presents	 a	 RGG	
domain	 capable	 of	 binding	 RNA	 at	 the	 C-terminus,	 a	 central	 SP1a	 and	 ryanodine	
receptor	 (SPRY)	 homology	 domain	 of	 unknown	 function,	 and	 a	 scaffold-associated	
region	 (SAR)-specific	 bipartite	DNA	binding	 domain	 (SAF)	 able	 to	 bind	 specific	DNA	
sequences	 at	 the	 N-terminus	 49,69.	 HnRNP-U	 was	 described	 to	 be	 necessary	 for	 a	
correct	 heart	 development	 in	 mice,	 mediating	 the	 splicing	 of	 the	 fundamental	
excitation-contraction	 coupling	 protein	 Junctin,	 and	 to	 negatively	 regulate	 RNAPII	
elongation	 in	 human	 cells	 by	 inhibiting	 the	 phosphorylation	 of	 the	 CTD	 70,71.	
Moreover,	hnRNP-U	was	shown	to	be	required	for	the	localization	of	the	Xist	RNA	on	
the	 X	 chromosome	 and	 for	 the	 consequent	 formation	 of	 the	 inactivated-X	
chromosome.	 In	 this	model,	hnRNP-U	 interacts	with	 the	Xist	 RNA	 through	 the	RGG	
domain	and	anchors	it	to	the	X	chromosome	binding	DNA	with	its	SAF	domain	72.	
HnRNP-K	 is	 a	 nucleic	 acid-binding	 protein	 that	 acts	 on	 its	 targets	 upon	 different	
cellular	 stimuli,	 integrating	different	 signaling	pathways.	Historically,	 it	was	 the	 first	
protein	 where	 a	 common	 RBD,	 the	 K-homology	 (KH)	 domain,	 was	 observed.	 This	
domain	was	later	found	in	numerous	other	RNA-binding	proteins.	From	the	structural	
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point	 of	 view,	 hnRNP-K	 possesses	 three	 KH-domains,	 an	 RGG	 region	 and	 a	 nuclear	
shuttling	 signal.	 It	 has	 been	 observed	 to	 participate	 to	 the	 regulation	 of	 mRNA	
splicing,	 stability	 and	 translation.	When	 bound	 to	 DNA,	 hnRNP-K	 can	 interact	 with	
transcription	factors	to	direct	gene	expression	or	repression,	and	also	with	chromatin	
remodelers	 to	 influence	 DNA	 organization.	 Furthermore,	 hnRNP-K	 was	 shown	 to	
recruit	 the	 termination-exonuclease	 XRN2	 on	 specific	 transcripts,	 regulating	
transcription	termination	49,73–75.	
As	 described,	 hnRNPs	 can	 have	 fundamental	 roles	 in	 the	 maturation	 of	 RNAs.	
Consequently,	the	misregulation	of	hnRNPs	might	result	in	the	incorrect	processing	of	
important	 cellular	 factors,	 possibly	 leading	 to	 a	 loss	 of	 cellular	 homeostasis	 and	 to	
pathological	conditions	76,77.	
1.3.2	hnRNPs	and	diseases	
Despite	 their	 ubiquitous	 expression,	 the	 deletion	 or	mutation	 of	 single	 hnRNP	 can	
result	 in	tissue-specific	diseases.	This	specificity	can	be	explained	either	by	a	tissue-
specific	 expression	 of	mRNA	 targets	 of	 the	RBP	or	 by	 a	 higher	 susceptibility	 of	 the	
tissue	to	changes	in	a	specific	PTGR	pathway	36.		
In	general,	a	genetic	mutation	affecting	the	RBP-mRNA	regulatory	axis	can	hit	either	
the	RBP	or	the	mRNA.	In	the	first	case,	the	mutation	could	occur	in	the	DNA	sequence	
coding	 for	 the	 RBD,	 rendering	 the	 protein	 unable	 to	 bind	 part	 or	 all	 of	 its	 target	
mRNAs,	 or	 in	 a	 position	 that	 will	 affect	 the	 behavior	 of	 the	 whole	 protein,	 for	
example	modifying	its	 localization	or	 interactions	with	other	proteins.	 In	the	second	
case,	the	mutation	in	the	specific	target	mRNA	could	make	it	inaccessible	to	the	RBP,	
therefore	 preventing	 the	 correct	 processing	 of	 the	 transcript	 36.	 The	 loss	 of	
interaction	 between	 the	 RBP	 and	 its	 target	 RNA	 might	 affect	 the	 splicing	 and	
processing	 of	 the	 latter,	 possibly	 leading	 to	 pathological	 conditions	 77.	 The	
misregulation	 of	 hnRNPs	 has	 been	 described	 in	 different	 pathologies,	 and	 in	
particular	in	tumors	and	neurodegenerative	diseases	(Fig.	5)	78.	
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Figure	5.	List	of	the	described	functions	and	link	to	diseases	of	hnRNPs.	Taken	and	modified	from	
Geuens,	Bouhy	and	Timmerman,	2016	78.	
HnRNP-A1	 was	 found	 to	 be	 overexpressed	 in	 different	 tumor	 samples	 and	 to	 be	
associated	 with	 metastasis	 and	 tumor	 proliferation,	 directly	 interacting	 with	 the	
mRNAs	 of	 well-described	 oncoproteins	 as	 HRAS	 and	 KRAS	 65,78–80.	 Furthermore,	
hnRNP-A1	 was	 observed	 to	 participate	 to	 the	 alternative-splicing	 of	 CD44,	 a	
transmembrane	 receptor	 described	 to	 be	 involved	 in	 tumorigenesis	 favoring	
epithelial-mesenchymal	 transition	 81.	HnRNP-C	was	 identified	as	a	 key	player	 in	 the	
splicing	 of	 the	 mRNA	 of	 the	 oncogene	 BRCA1.	 In	 fact,	 loss	 hnRNP-C	 induced	 a	
decrease	 of	 BRCA1	 inside	 the	 cells,	 together	 with	 other	 proteins	 involved	 in	 DNA	
repair,	eventually	favoring	tumorigenesis	82.	Moreover,	HnRNP-K	was	described	to	be	
deleted	in	several	samples	of	hematologic	malignancies,	successively	characterized	as	
a	haploinsufficient	 tumor	 suppressor,	 and	 to	be	 involved	 in	 tumorigenesis	affecting	
different	steps	of	RNA	maturation	83,84.		
	
Neurons	 are	 the	most	 polarized	 cells	 of	 the	 human	 body,	 demanding	 for	 a	 secure	
transport	 and	 a	 precise	 localization	 of	mRNAs	 in	 space	 and	 time,	 and	 the	 nervous	
system	is	described	as	the	tissue	presenting	the	highest	level	of	alternative	splicing	85.	
A	misregulation	of	hnRNPs,	and	in	general	of	RBPs,	in	neurons	could	therefore	impair	
the	correct	balance	between	splicing	isoforms	and	affect	the	correct	localization	and	
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translation	 of	 fundamental	 mRNAs,	 concurring	 to	 the	 development	 of	
neurodegenerative	 pathologies	 86–89.	 For	 example,	 hnRNP-A1	 downregulation	 was	
observed	to	associate	with	the	severity	of	various	neurodegenerative	disorders,	such	
as	 Alzheimer's	 disease	 (AD),	 spinal	muscular	 atrophy	 (SMA),	 fronto-temporal	 lobar	
degeneration	 (FTLD),	 amyotrophic	 lateral	 sclerosis	 (ALS)	 and	multiple	 sclerosis	 (MS)	
90,91.	Currently,	 five	hnRNPs	(A1,	G,	M,	Q	and	R)	are	 linked	to	SMA	78.	HnRNP-C	was	
described	 to	 contribute	 to	 AD	 by	 increasing	 the	 stability	 of	 the	 Amyloid	 Precursor	
Protein,	consequently	increasing	its	expression	56,92,93.	
FUS/TLS	(FUS),	also	classified	as	hnRNP-P2,	has	been	described	to	exert	a	vast	array	of	
functions	in	RNA	metabolism	and	also	to	bind	DNA	94.	Among	its	numerous	functions,	
FUS	is	involved	in	splicing,	interacts	with	RNAPII	CTD	regulating	the	phosphorylation	
on	Serine	2,	binds	alternative	poly-adenylation	sites	on	pre-mRNAs	to	determine	the	
final	 length	 of	 the	 transcripts,	 is	 involved	 in	 the	 repair	 of	 stress-induced	 DNA	
damages,	 binds	 transcriptionally	 active	 chromatin	 and	 regulates	 the	 gene	
transcription	of	the	manganese	superoxide	dismutase	95–100.	Given	the	multiple	roles	
inside	the	cells,	FUS	has	been	associated	to	multiple	diseases,	 in	particular	affecting	
the	 nervous	 system.	 Mutations	 of	 FUS	 have	 been	 identified	 as	 causative	 or	 risk	
factors	of	ALS	and	FTLD.	The	accumulation	and	aggregation	of	FUS	in	the	cytoplasm,	
and	less	frequently	in	the	nucleus,	is	the	major	feature	of	FUS	induced	ALS	and	FTLD,	
but	FUS	inclusions	have	been	observed	in	different	neurodegenerative	diseases.	The	
FUS	 insoluble	 aggregates	 inside	 and	 outside	 neuronal	 cells	 induce	 cellular	 stress,	
ultimately	 leading	 to	 neuronal	 degeneration.	 Moreover,	 inside	 the	 cytoplasm,	 the	
inclusion	 sequester	 RNAs	 of	 which	 misexpression	 could	 further	 impair	 cellular	
activities	101,102.	
	
HnRNPs	 interact	 with	 numerous	 RNAs,	 exerting	 a	 vast	 plethora	 of	 roles,	 and	 can	
modify	their	associations	also	in	response	to	determined	cellular	and	environmental	
stimuli.	Given	these	characteristics,	is	no	surprise	that	they	have	been	associated	with	
different	pathologies.	Future	investigations	will	for	sure	find	hnRNPs	involved	in	other	
cellular	processes	and	pathologies.		
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1.4		The	hnRNP	RALY	
RALY,	the	RNA-binding	protein	Associated	with	Lethal	Yellow	mutation,	is	a	member	of	
the	hnRNP	 family	 that	was	described	 for	 the	 first	 time	 in	mice	affected	by	 the	 “lethal	
yellow	mutation”.	 In	 these	animals,	a	deletion	of	170	kb	on	chromosome	2	eliminates	
the	coding	sequence	of	RALY,	the	entire	Eukaryotic	Initiation	Factor	2B	and	the	5’	region	
of	the	ASIP/Agouti	gene,	encoding	for	a	protein	involved	in	regulating	the	pigmentation	
of	 the	 coat.	 Ultimately,	 this	 deletion	 leads	 to	 the	 generation	 of	 a	 chimeric	 gene	
composed	by	the	first	non-coding	part	of	RALY	and	the	coding	sequence	of	ASIP/Agouti.	
This	 chimera	 will	 be	 under	 the	 control	 of	 RALY	 promoter,	 therefore	 resulting	 in	 an	
aberrant	 expression	 control	 during	 the	 embryogenesis.	 In	 heterozygosis,	 the	 deletion	
induces	a	yellow	fur	 in	the	animals,	while	 in	homozygosis	determines	the	death	of	the	
embryo	103,104.		
In	humans,	RALY	is	a	306	amino	acids	protein	containing	an	RRM	at	the	N-terminus,	two	
predicted	nuclear	 localization	signals	(NLSs)	 in	the	middle,	and	a	non	canonical	RGG	at	
the	 C-terminus	 (Fig.	 6A)	 105.	 This	 latter	 auxiliary	 domain	 was	 proposed	 to	 mediate	
protein-protein	 interactions,	but	since	RGGs	have	been	described	to	have	also	nucleic-
acids	binding	properties,	its	function	remains	elusive	39,42.	
RALY	was	classified	as	an	hnRNP	thanks	to	the	similarity	with	hnRNP-C,	particularly	high	
in	 the	 sequence	 coding	 for	 the	 RRM	 106,107.	 The	 gene	 coding	 for	 RALY	 is	 located	 on	
chromosome	20	and	produces	 two	 isoforms	of	 the	protein:	a	 longer	one,	RALY,	and	a	
shorter	one,	named	P542,	which	lacks	16	amino	acids	downstream	the	RRM	compared	
to	 RALY	 108.	 RALY	 is	 mainly	 localized	 inside	 the	 nucleus,	 but	 is	 also	 present	 in	 the	
cytoplasm	 (Fig.	 6B),	 where	 it	 has	 been	 observed	 to	 interact	 with	 the	 translational	
machinery	109.		
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Figure	 6.	 (A)	 Graphic	 representation	 of	 RALY.	 (B)	 HeLa	 cells	 were	 immunostained	 with	 antibody	
against	RALY	and	nuclei	were	stained	with	DAPI.	RALY	is	mainly	localized	in	the	nuclei,	but	is	excluded	
from	the	nucleoli.	
In	 human,	 RALY	 is	 ubiquitously	 expressed	 in	 all	 tissues,	 even	 if	 at	 different	 levels.	
Initially,	RALY	was	identified	in	human	as	a	cross-reacting	antigen	with	the	Epstein-Barr	
nuclear	 antigen	 1	 (EBNA1),	 a	 viral	 protein	 encoded	 by	 the	 Epstein-Barr	 virus	 110.	
Successively,	RALY	was	found	associated	with	components	of	the	spliceosome	and	of	the	
Exon	 Junction	 Complex	 (EJC),	 a	 protein	 machinery	 responsible	 to	 control	 the	 correct	
splicing	 of	 transcripts.	 However,	 its	 downregulation	 did	 not	 significantly	 affect	 the	
splicing	 of	 pre-mRNAs	 111,112.	 Thus,	 the	 role	 of	 RALY	 in	 the	 post-transcriptional	
modification	 of	 RNAs	 remains	 still	 elusive.	 Through	 proteomic	 analysis,	 RALY	 was	
observed	 to	 interact	 with	 the	 CTD	 of	 RNAPII	 and	 with	 proteins	 involved	 in	 RNA	
metabolism,	 such	 as	 the	 splicing	 factors	 U2AF65,	 PRP19,	 MATR3	 and	 EIF4A3,	 and	 in	
translational	 control	 105,113.	 In	 addition,	 RALY	 was	 recently	 characterized	 as	 a	
transcriptional	 co-factor,	 together	 with	 the	 long-non	 coding	 RNA	 LeXis,	 together	
involved	 in	 the	 transcriptional	 regulation	 of	 genes	 belonging	 to	 the	 cholesterol	
biosynthesis	 pathway	 in	 mouse	 liver	 114.	 Through	 proteomic	 analysis,	 RALY	 was	 also	
observed	to	interact	with	FUS,	but	this	association	is	still	uncharacterized	105.	However,	
given	the	many	 functions	exerted	by	FUS	 inside	the	cells,	 the	 interaction	of	RALY	with	
FUS	 opens	 the	 interesting	 possibility	 of	 shared	 roles	 and	 cooperation	 in	 RNA	
metabolism.	
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RALY	mRNA	was	found	to	be	upregulated	in	different	cancerous	tissues	such	as	ovarian,	
lung,	bladder,	brain	and	breast	cancers	as	well	as	in	multiple	myelomas	and	melanomas.	
In	particular,	 adenocarcinoma	 cell	 lines	presented	a	high	expression	of	RALY.	 In	 these	
cells,	 RALY	 was	 found	 to	 interact	 with	 YB-1,	 an	 RBP	 involved	 in	 alternative	 splicing,	
transcription	and	 translational	 regulation	of	 specific	mRNAs,	and	 in	 the	 repair	of	nicks	
and	breaks	into	double-stranded	DNA	115–118.	RALY	was	observed	to	be	required	for	the	
YB-1	 induced	 resistance	 to	 platinum-based	 drugs	 in	 adenocarcinoma	 cell	 lines	 115.	
Altogether,	 these	 observations	 suggest	 a	 potential	 involvement	 of	 RALY	 in	
tumorigenesis.	
Even	 if	 RALY	 was	 described	 in	 multiple	 occasions,	 its	 biological	 and	 molecular	 roles	
remain	elusive.	
	
 
2.	 Aim	of	My	PhD	Project	
RNA-binding	proteins	are	involved	in	all	the	steps	of	RNA	maturation,	virtually	regulating	
the	 expression	 of	 all	 proteins	 at	 the	 level	 of	 post-transcriptional	 gene	 regulation.	 The	
characterization	 of	 specific	 RBPs	 is	 therefore	 of	 central	 importance	 for	 the	
understanding	of	physiological	cellular	processes,	but	also	of	pathological	dynamics.	The	
RBP	 RALY	 is	 still	 largely	 uncharacterized,	 but	 its	 protein	 interactors	 and	 target	 RNAs	
suggest	an	involvement	at	different	steps	of	RNA	metabolism.	My	PhD	project	aimed	to	
the	expansion	of	the	characterization	of	RALY,	with	a	particular	focus	on	its	relationship	
with	 nuclear	 components,	 as	 chromatin,	 and	 with	 higher	 order	 cellular	 processes	 as	
transcription	and	cell	proliferation.	
The	backstory	of	RALY	
During	the	first	year	of	my	PhD,	I	mainly	participated	to	the	ongoing	characterization	of	
the	interaction	of	RALY	with	RNA.	In	fact,	RALY	was	classified	as	an	RBP,	given	the	high	
similarity	with	hnRNP-C,	but	its	ability	to	effectively	bind	RNA	and	the	identity	of	its	RNA	
targets	 were	 not	 yet	 described.	 These	 results	 were	 published	 in	 Rossi	 et	 al.	 and	 the	
experiments	 I	 contributed	 to	 served	 as	 a	 hint	 to	 start	 my	 own	 project	 109.	 We	
demonstrated	 that	 RALY	 binds	 RNA	 through	 its	 RRM,	 preferentially	 in	 the	 3’	 UTR	 of	
transcripts	and	specifically	on	poly-U	stretches.	We	identified	2929	RNAs	bound	by	RALY	
through	 RNA	 immunoprecipitation	 coupled	 with	 sequencing	 (RIP-seq)	 in	 MCF7	 cells.	
Gene	 ontology	 and	 pathway	 annotation	 enrichment	 analyses	 revealed	 that	 proteins	
coded	 by	 the	 RNAs	 interacting	 with	 RALY	 were	 significantly	 associated	 with	 different	
RNA	 metabolism	 related	 processes	 such	 as	 RNA	 processing,	 transport,	 splicing	 and	
translation.	 These	 results	 immediately	 appeared	 interesting	 given	 the	 enrichment	 of	
RNA	 metabolism	 and	 splicing	 related	 proteins	 in	 the	 interactome	 of	 RALY,	 further	
suggesting	 the	 involvement	 of	 RALY	 in	 RNA	 processing	 105.	 Interestingly,	 regulation	 of	
cell	 cycle	 and	 apoptosis	 were	 cellular	 processes	 also	 significantly	 enriched	 in	 the	
proteins	coded	by	RALY	mRNA	targets.		
We	 analyzed	 the	 impact	 of	 RALY	 downregulation	 on	 global	 gene	 expression	 through	
microarray	 analysis.	We	 found	217	misregulated	genes	 in	MCF7	 cells	 transfected	with	
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siRNA	 against	 RALY	 compared	 to	 control	 siRNA	 transfected	 cells.	 Gene	 Ontology	
enrichment	 analysis	 identified	 extracellular	 matrix	 organization	 and	 cell	 adhesion	 as	
biological	 processes	 significantly	 associated	with	 upregulated	 genes,	while	 cell	 growth	
and	 intracellular	 signal	 transduction	were	 significantly	 associated	with	 downregulated	
genes.	 Interestingly,	 both	 the	RIP-seq	and	 the	microarray	Gene	Ontology	enrichments	
suggested	 a	 connection	 between	 RALY	 and	 the	 regulation	 of	 cell	 proliferation.	 These	
results	 were	 supported	 by	 FACS	 analysis,	 which	 showed	 how	 the	 silencing	 of	 RALY	
contributed	to	the	alteration	of	cell	cycle	progression	in	Panc-1	cells,	with	a	partial	arrest	
in	 G0-G1	 phase.	 Finally,	 we	 also	 showed	 a	 connection	 of	 RALY	 with	 translation,	
identifying	RALY	on	polysomes	109.	The	results	of	this	work	are	presented	in	details	in	the	
Publications	section.		
	
While	 we	 were	 characterizing	 RALY,	 I	 was	 interested	 in	 understanding	 the	molecular	
function	 exerted	 by	 RALY	 on	 RNA.	 As	 described	 in	 the	 introduction,	 so	 far,	 RALY	was	
found	 to	 be	 part	 of	 the	 EJC	 and	 to	 interact	 with	 factors	 exerting	 prominent	 roles	 in	
splicing	 and	 in	 RNA	 processing,	 but	 the	 meaning	 of	 these	 associations	 was	 not	
understood	105,111,112.	Different	RBPs,	including	other	hnRNPs	such	as	hnRNP-C,	hnRNP-U	
and	hnRNP-K,	were	observed	to	bind	chromatin	to	use	it	as	a	docking	platform	to	exert	
their	role	in	RNA	processing	51,66,70,75,119.	Interestingly,	these	hnRNPs,	together	with	other	
RBPs	described	to	associate	with	chromatin,	like	FUS	and	Matrin	3,	were	included	in	the	
interactome	of	RALY	100,105,120.	These	connections	between	the	 interactors	of	RALY	and	
chromatin	 prompted	 me	 to	 investigate	 the	 possible	 association	 between	 RALY	 and	
chromatin.	 If	 subsisting,	 this	 association	 could	 have	 helped	 to	 understand	 the	 role	 of	
RALY	 in	RNA	metabolism.	Starting	 from	this	point,	 I	 successively	 studied	 the	effects	of	
RALY	downregulation	on	transcription	and	cell	proliferation.	
	
In	parallel,	I	tried	to	better	understand	the	involvement	of	RALY	in	splicing,	studying	the	
topic	with	multiple	approaches.	The	results	regarding	this	part	are	presented	after	the	
main	project	of	the	thesis,	in	the	“RALY	and	Splicing”	section.	
I	have	been	also	involved	in	MaDEleNA,	a	very	ambitious	and	challenging	project	aimed	
to	develop	an	innovative	device,	based	on	the	physics	of	“memristors”,	able	to	interface	
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and	sense	 the	activity	of	neurons.	More	details	 regarding	 this	project	 can	be	 found	 in	
the	MaDEleNA	section.	
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3. RESULTS	
3.1	 	 RALY	 interacts	 with	 chromatin	 in	 both	 an	 RNA-dependent	
and	-independent	manner	
As	 a	 preliminary	 observation	 of	 the	 possible	 interaction	 of	 RALY	 with	 chromatin	
components,	 HeLa	 cells	 were	 fractionated	 into	 soluble	 and	 chromatin-bound	 protein	
fractions,	and	the	presence	of	RALY	was	evaluated	through	Western	blot.	In	parallel,	the	
extracts	 were	 also	 treated	 with	 RNase	 A	 before	 fractionation	 to	 assess	 a	 possible	
involvement	 of	 RNA	 in	 determining	 the	 interaction,	 given	 the	 RNA-binding	 activity	 of	
RALY.	Histone	H3	(H3)	and	Actinin	were	used	as	chromatin-bound	and	soluble	fraction	
markers,	respectively.	RALY	was	found	to	interact	with	chromatin,	and,	interestingly,	the	
association	 showed	 a	 partial	 RNA-dependency	 (Fig.	 1A).	 In	 fact,	 upon	 RNase	 A	
treatment,	the	signal	of	RALY	decreased,	but	not	disappeared,	 in	the	chromatin-bound	
fraction	and	in	parallel	increased	in	the	soluble	fraction	(Fig.	1A).		
To	better	characterize	the	RALY-chromatin	 interaction,	the	cells	were	fractionated	 into	
four	 different	 fractions:	 cytosolic	 fraction,	 nuclear-soluble	 fraction,	 low-salt	 soluble	
chromatin	 and	 high-salt	 soluble	 chromatin	 fractions	 100,121.	 The	 cytosolic	 fraction	 (C)	
contains	 all	 the	 proteins	 outside	 of	 the	 nucleus.	 The	 nuclear-soluble	 fraction	 (NS)	
comprises	 the	 proteins	 that	 localize	 inside	 the	 nucleus	 but	 are	 not	 attached	 to	
chromatin.	The	 low-salt	soluble	chromatin	fraction	(LS)	contains	proteins	associated	to	
transcriptionally	 active	 chromatin	 and	 to	 transcription	 start	 sites	 (TSSs).	 The	 high-salt	
soluble	chromatin	fraction	(HS)	contains	proteins	associated	to	transcriptionally	inactive	
chromatin	and	bulky	complexes	strongly	associated	to	chromatin	121.	The	enrichment	of	
RALY	in	the	different	fractions	was	analyzed	by	Western	blot.	To	verify	the	successful	of	
the	 fractionation,	beta-Tubulin	 (Tubulin),	 the	 linker	histone	H1X	 (H1X),	and	histone	H3	
(H3),	 were	 respectively	 used	 as	 cytosolic,	 inactive	 chromatin	 and	 whole	 chromatin	
markers.	 The	 RNA-binding	 protein	 FUS	 was	 used	 as	 a	 fractionation	 control,	 given	 its	
already	described	localization,	and	as	a	comparison	for	RALY	with	another	hnRNP	94,100.	
As	expected,	the	linker	histone	H1X	was	found	in	the	HS	but	not	in	the	LS	fraction,	while	
histone	 H3	 was	 present	 in	 both	 the	 LS	 and	 HS	 fractions.	 By	 contrast,	 Tubulin	 was	
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enriched	 in	 the	 cytosolic	 fraction	 (Fig.	 1B).	 FUS	 confirmed	 the	 correctness	 of	 the	
protocol	behaving	as	described	by	Yang	et	al.,	showing	a	strong	enrichment	in	the	LS,	a	
weaker	 presence	 in	 the	NS	 and	HS,	 and	 being	 absent	 from	 the	 C	 (Fig.	 1B).	 RALY	was	
observed	 to	be	 faintly	present	 in	 the	 cytoplasmic	and	 in	 the	nuclear-soluble	 fractions,	
and	 strongly	 enriched	 in	 the	 fractions	 containing	 both	 transcriptionally	 active	 and	
inactive	 chromatin	 bound	 proteins	 (Fig.	 1B).	 Interestingly,	 RALY	 and	 FUS	 shared	 the	
localization	 in	 the	 transcriptionally	active	 fraction	of	 chromatin.	To	better	characterize	
the	 involvement	 of	 RNA	 in	 the	 RALY-chromatin	 interaction,	 the	 samples	were	 treated	
with	RNase	A	prior	 to	 fractionation.	Upon	RNase	A	treatment,	a	statistically	significant	
amount	of	RALY	shifted	from	the	LS	fraction	to	the	cytosolic	fraction	(Fig.	1C,	C	and	LS	
fractions).	On	 the	contrary,	 the	pool	of	RALY	associated	with	 transcriptionally	 inactive	
chromatin	was	not	significantly	affected	by	RNA	degradation	(Fig.	1C,	HS	fraction).		
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Figure		1.	RALY	is	associated	with	chromatin.	(A)	HeLa	cells	were	fractionated	into	chromatin-bound	
and	soluble	protein	 fractions.	Each	 fraction	was	subjected	 to	SDS/PAGE	and	Western	blot	with	 the	
indicated	antibodies.	Endogenous	RALY	is	present	in	both	the	chromatin-bound	and	soluble	fractions	
of	 proteins.	 (B)	HeLa	 cells	were	 fractionated	 into	 cytosol	 (C),	 nuclear	 soluble	 (NS),	 low-salt	 soluble	
chromatin	 (LS)	 and	 high-salt	 soluble	 chromatin	 (HS)	 fractions.	 Each	 fraction	 was	 subjected	 to	
SDS/PAGE	and	Western	blot	with	the	indicated	antibodies.	Endogenous	RALY	is	present	in	both	the	
LS	and	HS	fractions.	(C)	The	distribution	of	endogenous	RALY	was	examined	by	fractionation,	as	in	B,	
in	 presence	 (-RNase)	 or	 absence	 of	 RNA	 (+RNase).	 In	 absence	 of	 RNA,	 RALY	 decreased	 in	 the	 LS	
fraction	with	a	consequent	increase	in	the	C	fraction.	In	A	and	C,	the	levels	of	RALY	were	quantified	
by	band	densitometry	analysis.	The	graphs	show	the	mean	values	of	three	independent	experiments	
and	 compare	 the	 level	 of	 RALY	 in	 presence	 and	 absence	 of	 RNA	 in	 the	 chromatin	 and	 soluble	
fractions	 (A),	 and	 in	 the	C	 and	 LS	 fractions	 (C).	 Bars	 represent	mean	±	 S.D.	 P-value	was	 calculated	
using	unpaired	two-tailed	t-test.	*P<	0.05;	***P<0.001.	
Taken	together,	these	results	show	that	RALY	binds	to	both	transcriptionally	active	and	
inactive	 chromatin	 and	 that	 part	 of	 the	 interaction	 with	 transcriptionally	 active	
chromatin	is	dependent	on	the	presence	of	RNA.	
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3.2	 The	 interaction	 with	 chromatin	 is	 mediated	 by	 different	
domains	of	RALY	
To	identify	the	region	of	RALY	involved	in	the	interaction	with	chromatin,	we	designed	
constructs	coding	 for	different	domains	of	RALY	and	 tagged	 them	with	a	C-terminal	c-
Myc	 tag.	 The	 constructs	 coded	 for	 the	 full	 length	 protein	 (FL),	 the	 N-terminal	 region	
(amino	acids	1-225),	the	C-terminal	region	(amino	acids	143-306)	and	the	unstructured	
Glycine-rich	region	(amino	acids	225-306)	of	RALY	(Fig.	2A).	An	empty	expression	vector	
(EV)	was	used	as	negative	control.	The	expression	level	and	the	subcellular	 localization	
of	the	recombinant	proteins	were	examined	by	Western	blot	and	immunofluorescence	
analyses,	respectively	(Fig.	2B-C).		All	the	fragments	were	expressed	by	the	cells	and	all	
of	 them	were	mainly	 localized	 into	the	nucleus.	Notably,	 the	absence	of	 the	predicted	
NLSs	did	not	preclude	the	construct	226-306	to	accumulate	inside	the	nucleus	(Fig.	2C).		
The	 distribution	 of	 the	 different	 domains	 of	 RALY	 was	 then	 analyzed	 upon	 cell	
fractionation,	both	in	presence	and	absence	of	RNA	(-RNase	and	+RNase,	respectively).	
Although	all	 the	constructs	were	enriched	 in	 the	nuclear	 fractions,	only	 some	of	 them	
changed	their	localization	upon	RNase	A	treatment	(Fig.	2D).	In	particular,	in	absence	of	
RNA,	 the	 RMM-containing	 N-terminal	 part	 of	 RALY	 (1-225)	 disappeared	 from	 the	
nuclear-soluble	and	 low-salt	soluble	chromatin	fractions	(Fig.	2D,	NS	and	LS).	This	was	
not	observed	 instead	for	the	C-terminal	part	of	the	protein	(143-306)	(Fig.	2D,	NS	and	
LS).	These	results	suggest	that	RALY	can	 interact	with	nuclear	soluble	components	and	
transcriptionally	active	chromatin	using	either	the	N-	or	C-terminal	region,	and	that	the	
RRM-mediated	 interaction	 is	 RNA-dependent.	 To	 strengthen	 the	 hypothesis	 of	 two	
different	 types	of	binding,	 the	FL	RALY	only	partially	decreased	 in	both	 the	NS	and	 LS	
fractions	upon	RNase	A	treatment.	This	suggests	that	the	FL	RALY	pool	was	involved	in	
either	a	N-terminus-	or	C-terminus-mediated	interaction	with	the	proteins	of	the	NS	and	
LS	 fractions,	 and	 that	 the	 RNase	 A	 treatment	 only	 affected	 the	 pool	 of	 RALY	 binding	
chromatin	through	the	N-terminal	RRM	(Fig.	2D,	NS	and	LS).		 	
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Figure	 2.	RALY	 interacts	 with	 nuclear	 components	 using	 either	 the	 N-	 or	 C-terminal	 region.	 (A)	
Schematic	 representation	 of	 RALY-c-Myc	 tagged	 constructs.	 (B-D)	 RALY-c-Myc	 tagged	 constructs	
were	 transfected	 in	 HeLa	 cells	 for	 24	 hours.	 (B)	 Total	 lysates	 were	 subjected	 to	 SDS/PAGE	 and	
Western	blot	with	 the	 indicated	antibodies.	All	 the	constructs	are	expressed	by	HeLa	cells.	 (C)	The	
cellular	localization	of	RALY-c-Myc	tagged	mutants	was	verified	by	immunofluorescence	analysis	with	
anti-c-Myc	antibody	and	DAPI.	All	RALY	fragments	localize	inside	the	nucleus,	with	the	construct	143-
306	being	appreciably	detected	also	in	the	cytoplasm.	(D)	The	cells	were	fractionated,	in	presence	or	
absence	of	RNA,	into	cytosolic	(C),	nuclear-soluble	(NS),	low-salt	soluble	chromatin	(LS)	and	high-salt	
soluble	chromatin	(HS)	fractions.	Each	fraction	was	subjected	to	SDS/PAGE	and	Western	blot	with	the	
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indicated	antibodies.	The	N-	and	C-terminal	regions	are	both	involved	in	the	interaction	of	RALY	with	
transcriptionally	active	chromatin	(LS).	In	particular,	the	association	of	the	RRM-containing	mutant	of	
RALY	(1-225)	with	the	LS	fraction	is	dependent	on	RNA.	
 
Regarding	 the	association	with	 transcriptionally	 inactive	 chromatin,	 all	 the	domains	of	
RALY	localized	in	the	HS	fraction,	but	none	of	them	was	affected	by	RNase	A	treatment	
(Fig.	2D,	HS).	Further	experiments	are	needed	to	better	characterize	the	enrichment	of	
RALY	in	this	fraction.		
These	experiments	highlighted	 the	 importance	of	RNA	 in	 the	association	of	RALY	with	
nuclear	 components	 and	 prompted	 me	 to	 focus	 on	 the	 interaction	 of	 RALY	 with	
transcriptionally	 active	 chromatin.	 In	 fact,	 different	 RBPs	 previously	 identified	 in	 RALY	
interactome	are	tightly	associated	with	active	transcription	and	exert	their	role	 in	RNA	
processing	 in	 a	 co-transcriptional	 manner,	 interacting	 with	 the	 newly	 synthesized	
transcript,	 chromatin	 and	also	 the	 transcriptional	machinery	 3,4,69,71,75,98,105,113,119,122.	 To	
better	understand	the	link	of	RALY	with	active	transcription,	I	studied	their	relationship	
in	the	dynamic	and	physiological	environment	of	living	cells.		
3.3		The	localization	of	RALY	is	dependent	on	active	transcription.	
To	study	of	the	association	of	RALY	with	active	chromatin	in	vivo,	I	analyzed	the	behavior	
of	RALY	upon	the	block	of	transcription.	In	fact,	in	vivo,	the	majority	of	the	RNA	present	
on	chromatin	is	there	because	of	active	transcription.	Theoretically,	an	RBP	involved	in	
active	transcription	might	be	affected	by	the	absence	of	transcription	inside	the	nucleus.	
RNA	 synthesis	 was	 blocked	 by	 treating	 the	 cells	 with	 the	 transcription	 blocker	
Actinomycin	D	(ActD,	5	μg/ml)	for	different	periods	of	time	and	the	nuclear	amount	of	
RALY	 was	 measured	 by	 immunostaining	 using	 the	 High	 Content	 Imaging	 System	
“Operetta”	 (PerkinElmer)	 123.	 The	 inhibition	of	 transcription	was	verified	by	measuring	
the	newly	synthesized	RNA	through	the	 incorporation	of	the	Uracil-analogue	5-Ethynyl	
Uridine	(5EU)	into	new	transcripts,	followed	by	staining	with	the	fluorescent	dye	5FAM	
via	 Click	 reaction	 124.	 A	 scheme	 of	 the	 procedure	 and	 a	 representative	 staining	
experiment	are	depicted	in	Fig.	3A.		
The	 nuclear	 signal	 of	 RALY	 was	 observed	 to	 decrease	 over	 time	 during	 the	 ActD	
treatment	(Fig.	3B,	left),	suggesting	that	the	block	of	transcription	activated	either	RALY	
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degradation	 into	 the	 nucleus	 and	 de	 novo	 synthesis	 into	 the	 cytoplasm,	 or	 RALY	
translocation	 from	 the	nucleus	 to	 the	 cytoplasm.	No	 signal	 of	 new	RNA	was	detected	
within	the	nuclei	upon	ActD	treatment	(Fig.	3B,	right).		
The	 analysis	 of	 the	 samples	with	 a	more	 sensitive	microscope	 showed	 an	 increase	 of	
RALY	into	the	cytoplasm	upon	ActD	treatment	(Fig.	3C),	but	the	intensity	was	too	dim	to	
allow	 for	 a	 reliable	 quantitative	 measurement.	 	Again,	 the	 absence	 of	 5FAM	 signal	
confirmed	the	effectiveness	of	the	ActD	treatment	in	blocking	transcription	(Fig.	3C).			
	
Figure	3.	The	 localization	of	RALY	 is	dependent	on	active	transcription.	 (A)	On	the	left,	scheme	of	
the	staining	procedure	of	newly	synthesized	RNA	through	Click	reaction.	On	the	right,	representative	
experiment	of	newly	synthesized	RNA	visualization	through	5EU	incorporation	and	successive	5FAM	
staining,	together	with	DAPI	to	highlight	nuclei.	(B)	HeLa	cells	were	incubated	with	5EU	and	treated	
with	ActD	(5	μg/ml)	or	vehicle	(DMSO)	for	2,	4,	6	hours	and	the	amount	of	nuclear	RALY	was	assessed	
by	immunofluorescence	with	an	anti-RALY	antibody	by	the	High	Content	Imaging	System	“Operetta”.	
5EU	 was	 stained	 with	 5FAM	 through	 Click	 reaction.	 The	 amount	 of	 nuclear	 RALY	 significantly	
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decreases	 over	 time	 during	 the	 ActD	 treatment	 (left).	 The	 synthesis	 of	 new	 transcripts	 is	 blocked	
during	 ActD	 treatment	 (right).	 (C)	 HeLa	 cells	 were	 incubated	 with	 5EU	 and	 treated	 with	 ActD	 or	
DMSO	for	2	hours.	New	RNA	species	were	stained	through	Click	reaction	with	5FAM	while	RALY	was	
visualized	 by	 immunofluorescence	 with	 an	 anti-RALY	 antibody.	 Nuclei	 were	 highlighted	 with	 DAPI	
staining.	 After	 ActD	 treatment,	 there	 is	 no	 synthesis	 of	 new	 RNAs	 and	 RALY	 increases	 in	 the	
cytoplasm.	 The	 graphs	 in	 B	 represent	 the	 mean	 of	 the	 fluorescent	 signals	 detected	 over	 three	
independent	 experiments.	 Bars	 represent	mean	±	 S.D.	 P-value	was	 calculated	using	unpaired	 two-
tailed	t-test	(***P<0.001).		
To	discriminate	between	the	degradation	and	the	nucleus-cytosol	shift	hypotheses,	and	
to	 understand	 if	 a	 restricted	 population	 of	 RALY	 was	 affected	 by	 the	 block	 of	
transcription,	the	localization	of	RALY	was	studied	by	fractionation	of	cells	treated	with	
ActD,	together	with	or	without	the	proteasome	inhibitor	MG132.	Treating	with	ActD,	the	
level	of	RALY	in	the	low-salt	soluble	chromatin	fraction	significantly	decreased	over	time	
with	a	parallel	progressive	 increase	 in	 the	 cytosolic	 fraction	 (Fig.	 4A).	 The	 same	 result	
was	 observed	 when	 the	 cells	 were	 incubated	 with	 both	 ActD	 and	 MG132,	 while	 no	
changes	were	 observed	 upon	 treatment	with	MG132	 alone.	 These	 results	 prove	 that,	
upon	transcription	block,	RALY	shifts	from	the	nucleus	to	the	cytoplasm	instead	of	being	
degraded	by	the	proteasome	and	de	novo	synthesized	to	remain	outside	of	the	nucleus	
(Fig.	4B).	The	accumulation	of	Ubiquitin	in	the	total	protein	extract	was	used	as	a	control	
for	MG132	activity.	As	expected,	 the	MG132	 treated	 samples	 showed	higher	 levels	of	
Ubiquitin	compared	to	the	untreated	sample	(Fig.	4C).	 	
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Figure		4.	In	absence	of	transcription,	RALY	migrates	from	transcriptionally	active	chromatin	to	the	
cytoplasm.	(A)	HeLa	cells	were	treated	with	ActD	(5	μg/ml)	or	vehicle	(DMSO)	for	2,	4,	6	hours	and	
afterwards	 fractionated	 into	 cytosol	 (C),	 nuclear-soluble	 (NS),	 low-salt	 soluble	 chromatin	 (LS)	 and	
high-salt	 soluble	 chromatin	 (HS)	 fractions.	 Each	 fraction	was	 subjected	 to	 SDS/PAGE	 and	Western	
blot	 with	 the	 indicated	 antibodies.	 Endogenous	 RALY	 decreases	 in	 the	 LS	 fraction	 upon	 ActD	
treatment	 and	 progressively	 increases	 in	 the	 C	 fraction.	 (B)	 HeLa	 cells	 were	 treated	 with	 ActD	 (5	
μg/ml)	and/or	MG132	(5	μM)	for	2,	4	or	6	hours	and	afterwards	fractionated	as	 in	A.	Each	fraction	
was	 subjected	 to	 SDS/PAGE	 and	 Western	 blot	 with	 the	 indicated	 antibodies.	 Endogenous	 RALY	
decreases	from	the	LS	 fraction	only	 in	presence	of	ActD,	while	 is	not	affected	by	MG132	alone.	 (C)	
Total	cell	 lysates	of	HeLa	cells	 treated	with	ActD	 (5	μg/ml)	and/or	MG132	5	μM	were	subjected	to	
SDS/PAGE	and	Western	blot	with	 the	Ubiquitin	antibody.	The	 treatment	with	MG132,	blocking	 the	
proteasomal	 activity,	 induces	 an	 accumulation	 of	 Ubiquitin	 inside	 the	 cells	 compared	 to	 the	
untreated	condition.	In	A,	the	levels	of	RALY	in	the	LS	fractions	were	quantified	by	band	densitometry	
analysis.	The	graphs	show	the	mean	values	of	three	independent	experiments	and	compare	the	level	
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of	RALY	during	the	different	treatments	normalizing	on	the	untreated	condition	(T0).	Bars	represent	
mean	±	S.D.	P-value	was	calculated	using	unpaired	two-tailed	t-test	(*P<	0.05;	***P<0.001).	
These	results	demonstrate	that	RALY	localizes	on	transcriptionally	active	chromatin	in	a	
transcription-dependent	manner	and	that	without	ongoing	transcription,	RALY	migrates	
towards	the	cytoplasm.	These	observations	further	connect	RALY	to	active	transcription.	
3.4		The	downregulation	of	RALY	affects	transcription	
Given	 the	 strong	 effect	 that	 the	 block	 of	 transcription	 had	 on	 RALY	 localization,	 I	
wondered	whether	the	absence	of	RALY	could	somehow	affect	global	transcription.	To	
this	aim,	 I	developed	a	procedure	 to	measure	 the	synthesis	of	new	RNA	based	on	 the	
incorporation	of	5EU	 for	different	 intervals	of	 time	and	successive	staining	with	5FAM	
(Fig.	 5A).	 The	 technique	 was	 tested	 and	 optimized	 with	 preliminary	 experiments	 on	
HeLa	 cells	 treated	 with	 either	 DMSO,	 as	 a	 control,	 or	 Trichostatin	 A	 (TSA),	 a	 drug	
described	to	enhance	transcription	by	inhibiting	the	de-acetylation	of	chromatin	24,125.	In	
both	 the	 conditions,	 the	 new	 RNA	 species	 were	 observed	 to	 accumulate	 inside	 the	
nuclei	 along	 the	 incubations	with	5EU,	with	a	 faster	 increase	 in	TSA	 treated	 cells	 (Fig.	
5B).		
Therefore,	I	proceeded	with	the	measurement	of	RNA	synthesis	in	RALY	downregulated	
HeLa	cells.	RALY	was	downregulated	using	siRNAs	against	RALY	(si-RALY),	while	control	
cells	were	treated	with	non-targeting	siRNAs	(si-CTRL).	The	silencing	of	RALY	was	verified	
by	immunostaining	(Fig.	5C,	left	panel)	and	newly	synthesized	RNA	was	quantified	only	
in	the	nuclei	where	RALY	fluorescence	signal	was	below	a	determined	threshold,	so	to	
consider	 only	 successfully	 RALY	 downregulated	 cells.	 Interestingly,	 the	 levels	 of	 newly	
synthesized	 RNA	 showed	 a	 slower	 increase	 over	 time	 in	 RALY	 downregulated	 cells	
compared	to	controls	(Fig.	5C,	right	panel).		
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Figure	 5.	The	 downregulation	 of	 RALY	 determines	 a	 slower	 increase	 of	 new	 RNA	 species	 inside	
nuclei.	 (A)	 Representative	 scheme	 of	 the	 procedure	 to	measure	 the	 progressive	 synthesis	 of	 new	
nuclear	 RNA	 species.	 (B)	 HeLa	 cells	 were	 incubated	 with	 5EU	 and	 were	 then	 treated	 with	 either	
Trichostatin	A	 (TSA)	or	vector	 (DMSO)	 for	15,	30,	45	and	60	minutes.	5EU	was	successively	stained	
with	5FAM	to	visualize	the	transcripts	synthesized	over	every	time	frame.	The	amount	of	new	RNA	
increases	 over	 time	 in	 both	 the	 conditions,	 but	 the	 increase	 is	 faster	 in	 the	 TSA-treated	 cells,	
coherently	with	the	drug	biological	effects.	(C)	HeLa	cells	were	transfected	for	72	hours	either	with	si-
CTRL	 or	 si-RALY	 and	 afterwards	 incubated	 for	 15,	 30,	 45	 or	 60	minutes	 with	 5EU	 to	monitor	 the	
synthesis	of	new	RNA	species.	5EU	was	successively	stained	with	5FAM,	while	RALY	was	stained	with	
an	anti-RALY	antibody.	The	 images	were	acquired	with	 the	High	Content	 Imaging	System	Operetta	
(Perkin	Elmer)	and	analyzed	with	the	software	Harmony	(Perkin	Elmer).	On	the	left,	detection	of	the	
average	signal	of	RALY	 in	si-CTRL	and	si-RALY	transfected	cells.	On	the	right,	the	 increasing	amount	
over	 time	 of	 newly	 synthesized	 RNA.	 In	 si-RALY	 cells,	 newly	 synthesized	 RNA	 species	 accumulate	
more	slowly	 inside	 the	nucleus	compared	 to	 si-CTRL	cells.	B	 and	C	 show	the	mean	of	 the	signal	of	
four	distinct	samples	processed	during	the	same	experiment.	The	whole	experiment	was	repeated	3	
times,	giving	the	same	result.	Bars	represent	mean	±	S.D.	P-value	was	calculated	using	unpaired	two-
tailed	t-test	(*P<	0.05;	**P<0.01;	***P<0.001).	
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The	 most	 abundant	 RNA	 species	 inside	 the	 cells	 are	 ribosomal	 RNAs,	 which	 are	
transcribed	 inside	 the	 nucleoli	 by	 RNA	 Polymerase	 I.	 Because	 of	 this,	 following	 5EU	
incorporation	 into	 new	 RNAs	 and	 staining	 with	 5FAM,	 nucleoli	 emit	 an	 intense	
fluorescence	signal	 (Fig.	 3A	and	3C).	 Since	RALY	 is	excluded	 from	the	nucleoli	and	 the	
majority	of	 the	RBPs	participating	 to	 transcription	were	 referred	 to	RNAPII-dependent	
transcription,	 I	 specifically	 studied	 the	 newly	 RNAPII-synthesized	 RNAs	 in	 absence	 of	
RALY.	 To	 this	 aim,	 the	measurement	 of	 RNA	 synthesis	was	 performed	by	 treating	 the	
cells	 with	 a	 dose	 of	 ActD	 (125	 ng/ml)	 sufficient	 to	 block	 only	 RNA	 Polymerase	 I	
transcription	124.	This	treatment	sensibly	reduced	the	nucleolar	staining	(Fig.	6A).	Under	
these	conditions,	the	nuclear	level	of	newly	synthesized	RNA	in	si-RALY	transfected	cells	
still	increased	more	slowly	over	time	compared	to	si-CTRL	treated	cells	(Fig.	6B,	right).		 	
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Figure	 6.	 The	 downregulation	 of	 RALY	 determines	 a	 slower	 increase	 over	 time	 of	 new	 RNA	
Polymerase	II-transcribed	RNAs	inside	nuclei.	(A)	HeLa	cells	were	incubated	for	1	hour	with	5EU	and	
either	with	ActD	(125	ng/ml)	or	vector	(DMSO).	5EU	was	successively	stained	with	5FAM	to	visualize	
newly	synthesized	RNA	species.	The	treatment	with	a	mild	dose	of	ActD	only	blocks	RNA	Polymerase	
I-dependent	transcription,	greatly	diminishing	the	fluorescence	signal	of	 the	nucleoli.	 (B)	HeLa	cells	
were	transfected	for	72	hours	either	with	si-CTRL	or	si-RALY	and	afterwards	incubated	for	15,	30,	45	
or	60	minutes	with	ActD	(125	ng/ml)	and	5EU.	5EU	was	successively	stained	with	5FAM,	while	RALY	
was	stained	with	an	anti-RALY	antibody.	The	 images	were	acquired	with	 the	High	Content	 Imaging	
System	Operetta	(Perkin	Elmer)	and	analyzed	with	the	software	Harmony	(Perkin	Elmer).	On	the	left,	
detection	 of	 the	 average	 signal	 of	 RALY	 in	 si-CTRL	 and	 si-RALY	 transfected	 cells.	 On	 the	 right,	 the	
increasing	amount	over	time	of	newly	synthesized	RNA.	Also	in	a	condition	where	RNAPI-dependent	
transcription	was	blocked,	 in	 si-RALY	 cells	 newly	 synthesized	RNA	 species	 accumulate	more	 slowly	
inside	 nuclei	 compared	 to	 si-CTRL	 cells.	 B	 shows	 the	 mean	 of	 the	 signal	 of	 four	 distinct	 samples	
processed	 during	 the	 same	 experiment.	 The	 whole	 experiment	 was	 repeated	 3	 times,	 giving	 the	
same	result.	Bars	represent	mean	±	S.D.	P-value	was	calculated	using	unpaired	two-tailed	t-test	(*P<	
0.05).	
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To	 confirm	 the	 involvement	 of	 RALY	 in	 the	 downregulation	 of	 transcription	 and	 to	
eliminate	the	possible	contribution	of	off-target	effects	of	siRNAs,	stable	RALY	knockout	
HeLa	cells	were	generated	by	CRISPR/Cas9	technology.	Five	RNA-guides	targeting	either	
exon	1	or	exon	2	of	the	genomic	sequence	of	RALY	were	inserted	into	a	PX330	vector,	
which	 contained	 the	 sequence	 coding	 for	 the	 enzyme	 Cas9	 and	 the	 resistance	 to	
Puromycin.	After	 transfection,	 positively	 transfected	 cells	were	 selected	by	 incubation	
with	 Puromycin	 and	 single	 cell	 clones	 were	 isolated	 by	 serial	 dilutions	 (RALY	 KO).	 In	
parallel,	 as	a	 control,	 single	cell	 clones	of	HeLa	cells	 transfected	with	an	empty	PX330	
vector	were	also	isolated	(EV).	The	level	of	RALY	was	assessed	in	a	RALY	KO	and	an	EV	
clone	 both	 by	 Western	 blot	 and	 immunofluorescence	 analyses	 (Fig.	 7A).	 Then,	 the	
synthesis	of	new	nuclear	RNA	was	measured	over	time	both	in	the	untreated	and	mild	
ActD	 (125	ng/ml)	 treated	condition.	 In	both	 the	cases,	RALY	KO	cells	 showed	a	slower	
increase	of	newly	synthesized	RNA	inside	the	nuclei	compared	to	control	cells	(Fig.	7B).		 	
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Figure	7.	The	knock-out	of	RALY	determines,	as	for	the	RNAi	experiments,	a	slower	increase	over	
time	of	 new	RNA	 Polymerase	 II-transcribed	RNAs	 inside	 the	 nuclei.	 (A)	 RALY	was	 knocked-out	 in	
HeLa	cells	 through	CRISPR/Cas9	 technology.	On	 the	 left,	 cell	 lysates	of	a	RALY	KO	and	an	EV	clone	
were	subjected	to	SDS/PAGE	and	Western	blot	with	the	indicated	antibodies.	On	the	right,	RALY	KO	
and	EV	control	cells	were	stained	with	an	anti-RALY	antibody	and	processed	for	immunofluorescence	
analysis.	With	both	the	techniques,	RALY	was	not	detected	in	the	cells	after	CRISPR/Cas9	mediated	
knock-out.	(B)	RALY	KO	and	EV	control	cells	were	incubated	for	15,	30,	45	or	60	minutes	with	5EU	in	
absence	(left)	or	presence	(right)	of	ActD	(125	ng/ml).	5EU	was	successively	stained	with	5FAM.	The	
images	of	the	samples	were	acquired	with	the	High	Content	Imaging	System	Operetta	(Perkin	Elmer)	
and	 analyzed	with	 the	 software	Harmony	 (Perkin	 Elmer).	 The	 graphs	 show	 the	 increasing	 amount	
over	 time	 of	 newly	 synthesized	 RNA.	 In	 both	 the	 conditions,	 RALY	 KO	 cells	 showed	 a	 slower	
accumulation	of	newly	synthesized	RNA	species	 inside	 the	nucleus	compared	 to	EV	control	cells.	 B	
shows	 the	mean	of	 the	signal	of	 four	distinct	 samples	processed	during	 the	same	experiment.	The	
whole	experiment	was	repeated	3	times,	giving	the	same	result.	Bars	represent	mean	±	S.D.	P-value	
was	calculated	using	unpaired	two-tailed	t-test	(*P<	0.05;	**P<0.01;	***P<0.001).	
These	results	confirmed	the	RNAi	experiments	 (Fig.	5B	and	6B)	and	showed	that	both	
the	 downregulation	 and	 absence	 of	 RALY	 determine	 a	 slower	 increase	 over	 time	 of	
newly	RNAPII-synthesized	RNA	species	inside	the	nuclei.		
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The	 decrease	 in	 the	 amount	 of	 newly	 synthesized	 RNA	 in	 RALY	 downregulated	 cells	
could	 be	 caused	 either	 by	 a	 diminishment	 in	 RNAPII	 productivity,	 specifically	 in	 the	
elongation	phase,	or	by	a	decreased	number	of	transcriptional	events.		
3.5		The	absence	of	RALY	does	not	impair	RNAPII	elongation	
Between	the	two	possible	reasons	that	could	have	explained	the	diminished	synthesis	of	
RNAs	upon	RALY	downregulation,	I	decided	to	first	study	RNAPII	elongation	rate.	In	fact,	
previous	experiments	gave	the	hint	for	a	possible	influence	of	RALY	on	RNAPII	dynamics.	
We	recently	observed	that	the	silencing	of	RALY	induced	a	strong	downregulation	of	the	
linker	 histone	 H1X	 in	 both	 its	 RNA	 and	 protein	 forms	 109.	 Linker	 histones	 bind	 to	
nucleosomes	near	the	entry/exit	sites	of	the	linker	DNA	and	their	commonly	attributed	
function	 is	 to	 stabilize	 highly	 condensed	 chromatin	 126.	 However,	 they	 have	 been	
described	 to	 participate	 to	 different	 processes,	 including	 gene	 expression	 regulation,	
indicating	different	roles	beyond	mere	structural	components	of	chromatin	127–130.	The	
histone	H1	family	is	composed	by	11	members,	of	which	H1X	is	the	least	characterized.	
H1X	has	been	shown	to	accumulate	inside	nucleoli	during	the	G1	phase	of	the	cell	cycle	
and	to	be	instead	distributed	across	the	entire	nucleus	in	the	S	phase	131.	Furthermore,	
H1X	was	observed	to	be	preferentially	located	at	the	chromosome	periphery	in	mitosis,	
and	 its	 ablation	 from	 the	 cells	 induced	 defects	 in	 chromosome	 alignment	 and	
segregation	 132.	 Mayor	 et	 al.	 observed	 H1X	 to	 co-localize	 with	 RNAPII	 on	 actively	
transcribed	genes,	proposing	it	to	regulate	RNAPII	elongation	speed	to	influence	splicing	
133.	Given	this	association	and	prompted	by	the	effects	of	the	downregulation	of	RALY	on	
H1X	expression,	 I	measured	RNAPII	 elongation	 speed	 in	 si-RALY	 transfected	HeLa	 cells	
134.		
RNAPII-dependent	transcription	was	blocked	by	treating	si-CTRL	and	si-RALY	transfected	
cells	with	 the	 specific	 and	 reversible	 RNAPII	 inhibitor	 DRB	 for	 3	 hours	 135.	 During	 this	
incubation,	 the	 pre-mRNAs	 inside	 the	 cells	 are	 either	 processed	 or	 degraded,	 but	 no	
new	 RNA	 is	 transcribed	 by	 RNAPII.	 The	 cells	 were	 successively	 washed	 with	 PBS	 to	
eliminate	DRB	and	were	then	incubated	with	warm	medium	to	recover	transcription	in	a	
synchronized	manner.	 Total	 RNA	was	 extracted	 at	 5	minute	 intervals	 till	 reaching	 120	
minutes	after	transcription	recovery.	Along	the	increasing	intervals,	RNAPII	will	 localize	
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at	different	positions	along	transcribed	genes,	depending	on	its	elongation	speed.	Using	
different	exon-intron	primer	pairs	on	long	genes,	it	is	possible	to	detect	its	position,	and	
therefore	 speed,	 through	 qRT-PCR.	 Every	 measured	 signal	 was	 normalized	 on	 the	
respective	 result	 obtained	 in	 si-CTRL	 and	 si-RALY	 cells	 not	 treated	 with	 DRB	 (UT).	 A	
resuming	scheme	of	the	technique	is	depicted	in	Fig.	8.		
	
	
Figure	8.	Measurement	of	RNAPII	elongation	speed.	RNAPII-dependent	transcription	 is	blocked	by	
treatment	with	DRB	 for	 3	 hours	 and	 synchronously	 re-activated	by	 incubation	of	 the	 cells	 in	 fresh	
medium.	 After	 re-activation,	 RNAPII	 starts	 again	 to	 transcribe	 genes.	 By	 extracting	 total	 RNA	 at	
different	times	after	re-activation	is	possible	to	detect	the	position	of	RNAPII	through	qRT-PCR	using	
exon-intron	 spanning	 primers	 on	 long	 genes.	 The	 procedure	 is	 described	 in	 details	 by	 Singh	 and	
Padgett	134.		
RNAPII	 elongation	 speed	 was	 measured	 on	 the	 pre-mRNAs	 of	 ITPR1,	 OPA1	 and	
CTNNBL1,	which	were	 selected	due	 to	 their	 length.	 In	 fact,	 long	genes	are	needed	 for	
this	technique	in	order	to	distinguish	the	localization	of	RNAPII	at	5	minute	intervals	of	
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transcription.	 In	 addition,	 these	 genes	 showed	 different	 expression	 levels	 upon	 RALY	
downregulation,	 allowing	 a	more	detailed	 study	of	 the	 connection	between	RALY	 and	
RNAPII-dependent	 transcription.	 More	 specifically,	 in	 si-RALY	 transfected	 cells,	 ITPR1	
level	 was	 found	 to	 be	 unchanged,	 while	 OPA1	 and	 CTNNBL1	 were	 measured	 to	 be	
respectively	upregulated	and	downregulated	compared	to	si-CTRL	cells	(Fig.	9A).		
For	the	analysis	of	the	elongation	rate,	the	first	time	point	presenting	an	average	signal	
above	 the	 10%	 of	 the	 UT	 condition	 was	 considered	 as	 the	 moment	 in	 which	 RNAPII	
reached	 that	 specific	 sequence.	For	all	 the	analyzed	genes,	RNAPII	elongation	 rate	did	
not	 significantly	 differ	 between	 si-CTRL	 and	 si-RALY	 transfected	 HeLa	 cells	 (Fig.	 9B-D,	
Table	1).	However,	in	some	cases,	a	hint	of	transcription	slow	down	was	noticeable	in	si-
RALY	 cells:	 further	 experiments	 with	 more	 sensitive	 approaches	 could	 analyze	 more	
precisely	the	elongation	rate	of	RNAPII	in	response	to	RALY	downregulation.	
Interestingly,	 in	our	experiments,	the	amount	of	synthesized	pre-mRNA	was	constantly	
lower	 in	 RALY	 downregulated	 cells	 in	 respect	 to	 control	 cells,	 suggesting	 that	 even	 if	
RNAPII	elongation	rate	was	not	significantly	affected,	a	lower	number	of	transcriptional	
events	was	taking	place.		
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Figure	9.	The	downregulation	of	RALY	does	not	affect	RNAPII	elongation	rate.	(A)	HeLa	cells	were	
transfected	 for	 72	 hours	 either	 with	 si-CTRL	 or	 si-RALY.	 The	 expression	 level	 of	 ITPR1,	OPA1,	 and	
CTNNBL1	mRNAs	was	quantified	by	qRT-PCR	and	normalized	on	GAPDH.	 The	 level	 of	 ITPR1	mRNA	
does	not	significantly	change,	while	OPA1	and	CTNNBL1	levels	respectively	increase	and	decrease	in	
si-RALY	cells	compared	to	si-CTRL	cells.	The	graph	shows	the	mean	of	three	independent	experiments	
±	S.D.		P-value	was	calculated	using	an	unpaired	two	tailed	t-test	(**P<0.01)	between	si-RALY	and	si-
CTRL	transfected	cells.	(B-D).	HeLa	cells	were	transfected	for	72	hours	either	with	si-CTRL	or	si-RALY	
and	successively	treated	with	100μM	DRB	for	3	hours	to	block	RNAPII-dependent	transcription.	The	
cells	were	then	incubated	in	fresh	medium	after	DRB	removal	to	recover	transcription.	Total	RNA	was	
extracted	at	5	minute	intervals	and	analyzed	by	qRT-PCR.	The	expression	values	are	plotted	relative	
to	the	expression	level	of	the	no	DRB	treated	control,	which	is	set	to	1	in	all	experiments.	RALY	does	
not	 impair	 RNAPII	 elongation	 rate.	 The	 graphs	 show	 the	mean	 of	 the	 signal	 of	 three	 independent	
experiments.	Bars	represent	mean	±	S.D.		
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Table	1.	Calculation	of	the	average	RNAPII	elongation	rate	in	si-CTRL	and	si-RALY	transfected	HeLa	
cells.	
Transcription	is	the	initial	step	of	the	genetic	information	flow,	which	will	ultimately	lead	
to	the	synthesis	of	proteins.	For	this	reason,	it	is	at	the	basis	of	the	regulation	of	higher	
order	 cellular	 processes,	 as	 for	 example	 the	 renewal	 of	 cellular	 components,	 cell	
proliferation	and	the	response	to	external	stimuli.	Vice	versa,	these	processes	regulate	
transcription	 of	 specific	 sets	 of	 genes	 to	 determine	 cellular	 behavior.	 The	 decrease	 in	
transcription	observed	upon	RALY	downregulation/KO	could	therefore	be	connected	to	
the	 misregulation	 of	 other	 cellular	 processes,	 such	 as	 cell	 proliferation.	 In	 fact,	 we	
recently	 described	 how	 the	 silencing	 of	 RALY	 determined	 the	 downregulation	 of	
different	genes	involved	in	the	regulation	of	cell	cycle	and	how	RALY	bound	RNAs	were	
enriched	 in	 transcripts	 coding	 for	 proteins	 involved	 in	 cell	 cycle	 progression	 109.	
Transcription	 is	 tightly	associated	with	cell	 growth:	highly	proliferating	cells	 show	high	
levels	 of	 transcription	 to	 sustain	 the	 intense	 demand	 of	 gene	 products	 necessary	 to	
maintain	 a	 quick	 growth	 rate.	 To	 this	 aim,	 these	 cells	 tend	 to	 overexpress	 versatile	
transcription	factors,	such	as	members	of	the	MYC	and	EF2	family,	which	can	supply	the	
necessary	 gene	 products	 to	 promote	 their	 growth	 and	 division	 136.	 Taken	 all	 these	
considerations	 together,	 I	 investigated	 the	 possible	 involvement	 of	 RALY	 in	 the	
regulation	of	different	cell	cycle-related	genes.	 In	fact,	the	absence	of	RALY	could	alter	
the	processing	of	 the	mRNA	coding	 for	 factors	 involved	 in	cell	proliferation,	ultimately	
affecting	cell	growth	and	transcription.		
si#CTRL si#RALY si#CTRL si#RALY
ITPR1-Ex1#Ex3 23.5 10 10 2.32 2.32
ITPR1-Ex1#Ex4 28 15 15 1.86 1.86
ITPR1-Ex1#Ex5 133 40 40 3.33 3.33
ITPR1-Ex1#Ex27 190 55 55 3.46 3.46
OPA1-Ex1#Ex29 100 30 35 3.33 2.86
CTNNBL1-Ex1#Ex5 64 25 25 2.5 2.5
2.8±0.66 2.72±0.61
Time-to-transcribe-(min)- Elongation-rate-(kb/min)
Gene-Region Length-(kb)
Average/elongation/rate
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3.6	 	 The	 downregulation	 of	 RALY	 impairs	 the	 expression	 of	 cell	
proliferation	related	genes	
To	study	the	effects	of	the	absence	of	RALY	on	gene	expression,	we	analyzed	the	gene	
expression	 profile	 of	 si-RALY	 transfected	 HeLa	 cells	 through	 microarray.	 We	 used	 a	
HTA2.0	microarray	 (Affymetrix	Human	Transcriptome	Array)	 to	analyze	 three	different	
biological	replicas	of	si-CTRL	and	si-RALY	transfected	HeLa	cells.	The	levels	of	RALY	were	
measured	 by	 qRT-PCR	 and	 were	 detected	 to	 be	 lower	 than	 the	 10%	 in	 si-RALY	
transfected	 cells	 compared	 to	 si-CTRL	 cells	 (data	 not	 shown).	 Upon	 RALY	
downregulation,	we	found	1971	differentially	expressed	genes	(Table	2	in	Appendix),	of	
which	919	were	upregulated	and	1052	were	downregulated	(Fig.	10A).		The	majority	of	
the	 variations	 were	 observed	 in	 protein	 coding	 transcripts	 (93.5%),	 with	 a	 small	
percentage	of	non-coding	RNAs,	generally	higher	among	upregulated	genes	(3%	of	long	
non-coding	 RNAs)	 (Fig.	 10B).	 Functional	 annotation	 enrichment	 analysis	 by	 Gene	
Ontology	and	pathway	databases	identified	extracellular	matrix	organization,	regulation	
of	cell	motility	and	cell	adhesion	as	biological	processes	significantly	associated	with	the	
upregulated	genes.	On	the	other	hand,	cell	cycle	control	and	RNA	splicing	were	the	two	
broad	 themes	 more	 strongly	 associated	 with	 the	 downregulated	 genes	 upon	 RALY	
silencing	 (Fig.	 10C	 and	 Table	 3	 in	 Appendix).	 Both	 in	 HeLa	 and	 MCF7	 cells,	 a	 cell	
proliferation	related	class	resulted	to	be	an	enriched	class	among	downregulated	genes	
in	absence	of	RALY.		
Interestingly,	several	genes	coding	for	transcription-promoting	factors	were	also	present	
in	the	downregulated	genes	upon	RALY	silencing	(Table	2	in	Appendix).	
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Figure	 10.	 RALY	 silencing	 alters	 the	 transcriptome	 of	 HeLa	 cells.	 Three	 independent	 microarray	
experiments	were	performed	using	RNA	preparations	from	three	 independent	biological	replicates.	
HeLa	cells	were	transfected	for	72	hours	with	either	si-RALY	or	si-CTRL.	(A)	MA	plot	of	RALY	silencing	
transcriptome	profiling.	For	each	gene,	the	average	log10	signal	against	the	RALY	silencing	log2	Fold	
Change	(si-RALY	versus	si-CTRL)	 is	plotted.	Genes	significantly	upregulated	(blue)	or	downregulated	
(red)	upon	RALY	silencing	are	highlighted.	 (B)	Classification	of	differentially	expressed	genes	(DEGs)	
upon	RALY	silencing	according	to	RNA	classes.	(C)	Functional	annotation	enrichment	analysis	of	RALY	
upregulated	 and	 downregulated	 genes.	 The	 heat	 map,	 colored	 by	 enrichment	 p-value,	 displays	
enriched	classes	from	Gene	Ontology	terms	and	KEGG	or	REACTOME	pathways.	The	number	of	DEGs	
falling	in	each	category	is	displayed	inside	each	tile.	
	 45	
	
The	enrichments	of	cell	cycle-	and	transcription-related	genes	suggested	to	focus	on	the	
downregulated	genes	upon	RALY	silencing.		
To	validate	the	downregulation	events	detected	by	microarray,	 the	expression	 level	of	
factors	 promoting	 transcription	 and/or	 cell	 proliferation	 was	 measured	 by	 qRT-PCR.	
More	 specifically,	 for	 the	 cell	 growth	 I	 analyzed	 Cyclin	 B1,	 Cyclin	 B2	 and	 the	 Cyclin	
Dependent	Kinase	1	 (CCNB1,	CCNB2	and	CDK1,	respectively),	which	together	drive	 the	
G2/M	transition;	Cyclin	E1	and	Cyclin	E2	(CCNE1	and	CCNE2),	two	regulators	of	the	entry	
in	 S	 phase;	 the	M-phase	 inducer	 phosphatase	 1	 (CDC25A),	 a	 phosphatase	 involved	 in	
both	 the	 S-phase	 entry,	 acting	 on	 the	 CCNE1/Cdk2	 complex,	 and	 the	 G2-phase	
transition,	participating	to	the	activation	of	CCNB1/Cdk1	137–139.	Regarding	the	regulation	
of	 transcription	 instead,	 I	 analyzed	 Cyclin	 T1	 (CCNT1),	 member	 of	 the	 positive	
transcription	 elongation	 factor;	GTF2A1	 and	GTF2E2,	 subunits	 of	 general	 transcription	
factors	important	for	the	assembly	of	the	RNAPII	machinery	on	the	promoter	and	for	the	
initiation	of	 transcription;	and	 the	elongation	 factor	ELL2	 (ELL2),	member	of	 the	super	
elongation	 complex	 2,21,140–142.	 In	 addition,	 I	 measured	 also	 the	 RNA	 levels	 of	 SPT16	
(SUPT16H)	 and	 SSRP1	 (SSRP1),	 subunits	 of	 the	 chromatin	 remodeling	 FACT	 complex,	
which	 with	 its	 chromatin	 relaxing	 activity	 favors	 the	 activity	 of	 RNAPII	 throughout	
nucleosomes,	 and	 of	 the	 transcription	 factor	 Dp-1	 (TFDP1),	 a	 dimerization	 partner	 of	
E2F1-6	that	stimulates	E2F	dependent	transcription	143–146.		
All	the	target	mRNAs	were	found	to	be	downregulated	in	si-RALY	transfected	HeLa	cells,	
confirming	 the	microarray	 analysis	 (Fig.	 11A).	 In	 addition,	 the	protein	 levels	 of	 CCNE1	
and	CCNT1	were	measured	by	Western	blot	analysis.	Both	the	proteins	were	found	to	be	
downregulated	in	si-RALY	compared	to	si-CTRL	transfected	cells	(Fig.	11B	and	C).	
Taken	 together,	 these	 results	 show	 that	 the	 silencing	 of	 RALY	 induces	 a	 broad	
downregulation	of	transcription	and	cell	proliferation	related	genes,	possibly	explaining	
the	 reduced	 RNAPII-dependent	 transcription	 phenotype	 and	 the	 reduction	 in	 cell	
proliferation	observed	by	Rossi	et	al.	109.		
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Figure	11.	Validation	of	the	microarray	results	for	the	downregulated	genes	upon	RALY	silencing.	
HeLa	cells	were	transfected	either	with	si-RALY	or	si-CTRL	 for	72	hours	and	total	RNA	and	proteins	
were	 extracted.	 (A)	 The	 mRNA	 level	 of	 different	 factors	 promoting	 proliferation	 (CCNB1,	 CCNB2,	
CCNE1,	CDK1,	CDC25A,	TFDP1)	 and	 transcription	 (CCNT1,	 GTF2A1,	GTF2E2,	ELL2,	 SUPT16H,	 SSRP1)	
were	measured	by	qRT-PCR	and	normalized	on	GAPDH.	As	in	the	microarray	analysis,	all	the	analyzed	
genes	 were	 found	 to	 be	 less	 expressed	 in	 si-RALY	 compared	 to	 si-CTRL	 cells.	 (B-C)	 Total	 protein	
extracts	were	subjected	to	SDS/PAGE	and	Western	blot	analysis	with	the	indicated	antibodies	(on	the	
left).	The	levels	of	CCNE1	(B)	and	CCNT1	(C)	were	measured	by	band	densitometry	analysis	(on	the	
right)	and	were	found	to	be	downregulated	in	si-RALY	compared	to	si-CTRL	transfected	cells.	All	the	
graphs	of	the	figure	show	the	mean	of	three	independent	experiments	±	S.D.	P-value	was	calculated	
using	an	unpaired	two	tailed	t-test	(*P<0.05;	**P<0.01;	***P<0.001).	
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3.7		RALY	regulates	the	expression	of	E2F1	
In	 order	 to	 improve	 the	 functional	 characterization	 of	 the	 transcripts	 presenting	 an	
altered	expression	upon	RALY	 silencing,	we	performed	a	gene	 set	enrichment	analysis	
(GSEA).	This	process	allows	to	compare	the	list	of	misregulated	genes	from	a	microarray	
analysis	 with	 the	 collection	 of	 “Hallmark”	 annotated	 gene	 sets	 provided	 by	 the	
Molecular	 Signatures	 Database	 (MSigDB),	 detecting	 enrichments	 in	 specific	 gene	
families	 and	 cellular	 functions	 147.	 This	 analysis	 identified	 “E2F	 targets”	 as	 the	 most	
significantly	enriched	class	among	genes	downregulated	upon	RALY	silencing	(Fig.	12A).	
This	 gene	 set,	 according	 to	 the	MSigDB	definition,	 includes	 “genes	 encoding	 cell	 cycle	
related	targets	of	E2F	transcription	factors”.		
The	E2F	family	comprises	eight	transcription	factors	playing	key	roles	in	the	regulation	of	
cell	 cycle	 progression.	 Its	 members	 can	 be	 divided	 into	 activators	 (E2F1-3)	 and	
repressors	 (E2F4-5,	 E2F6,	 E2F7-8)	 of	 cell	 proliferation.	 In	 particular,	 the	 E2F1-3	 group,	
regulating	the	transactivation	of	target	genes	necessary	for	the	G1/S	phase	transition	of	
the	 cell	 cycle,	was	 found	 to	 be	 downregulated	 upon	 RALY	 silencing	 in	 the	microarray	
results	 (Table	 2	 in	 Appendix)	 146,148–150.	 Interestingly,	 E2F1	 and	 E2F2	 mRNAs	 were	
detected	as	RALY	mRNA	targets	in	the	RIP-seq	analysis	performed	by	Rossi	et	al.	in	MCF7	
cells	(Fig.	12B)	109.	
Among	the	activators	of	the	E2F	family	 I	 focused	on	E2F1,	a	key	character	of	cell	cycle	
regulation	and	apoptosis	 induction,	also	involved	in	carcinogenesis	when	misexpressed	
136,151–154.	To	validate	the	microarray	analysis,	the	downregulation	of	E2F1	in	response	to	
RALY	 silencing	was	 confirmed	by	qRT-PCR	and	Western	blot	 analyses.	Both	 the	mRNA	
and	 protein	 forms	 of	 E2F1	 resulted	 to	 be	 downregulated	 in	 si-RALY	 transfected	 HeLa	
cells	(Fig.	12C-D,	respectively).		
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Figure	 12.	RALY	 regulates	 the	 expression	 of	 E2F1.	 (A)	 Functional	 map	 of	 global	 changes	 in	 gene	
expression	in	response	to	RALY	silencing.	Enrichment	results	from	GSEA	were	mapped	as	a	network	
of	gene	 sets	 (nodes)	 related	by	mutual	overlap	 (edges),	where	blue	 identifies	upregulated	and	 red	
downregulated	gene	sets.	The	size	of	each	node	is	proportional	to	the	size	of	the	gene	set.	The	size	of	
each	 edge	 is	 proportional	 to	 the	mutual	 overlap	between	 two	nodes.	 The	 gene	 set	 “E2F_targets”,	
containing	“genes	encoding	cell	cycle	related	targets	of	E2F	transcription	factors”,	resulted	to	be	the	
most	enriched	in	downregulated	genes	upon	RALY	silencing.	(B)	The	mRNAs	coding	for	E2F1	and	E2F2	
were	 found	to	be	enriched	 in	RALY-containing	 immunoprecipitated	particles	 in	 the	RIP-seq	analysis	
performed	in	MCF7	cells	109.	On	the	contrary,	no	enrichments	were	detected	for	the	other	members	
of	the	E2F	family.	 (C-D)	HeLa	cells	were	transfected	either	with	si-CTRL	or	si-RALY	for	72	hours	and	
both	total	RNA	and	total	protein	extracts	were	collected.	The	RNA	was	analyzed	by	qRT-PCR	and	the	
signals	normalized	on	GAPDH,	while	proteins	were	subjected	to	SDS/PAGE	and	Western	blot	with	the	
indicated	antibodies	followed	by	band	densitometry	analysis.	Both	the	(C)	E2F1	mRNA	and	(D)	E2F1		
protein	 are	 downregulated	 in	 HeLa	 cells	 silenced	 for	 RALY.	 The	 graphs	 show	 the	 mean	 of	 three	
independent	 experiments	 ±	 S.D.	 P-value	 was	 calculated	 using	 an	 unpaired	 two	 tailed	 t-test	
(**P<0.01).		
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Successively,	 I	 analyzed	 the	direct	 interaction	between	RALY	 and	E2F1	mRNA	 through	
RNA	immunoprecipitation	in	UV-crosslinked	HeLa	cells.	E2F1	mRNA	was	observed	to	be	
enriched	 in	 RALY-containing	 immunoprecipitated	 complexes	 (Fig.	 13A).	 RALY	 and	
GAPDH	mRNAs	were	respectively	used	as	positive	and	negative	controls	 (Fig.	13A)	 109.	
We	previously	observed	RALY	to	preferentially	interact	with	poly-U	stretches	of	four	or	
more	Uridines	 in	 the	 3’UTR	 region	of	 transcripts	 109.	 To	 confirm	 the	direct	 interaction	
and	 to	 identify	 the	 region	bound	by	RALY	on	E2F1	mRNA,	 I	 selected	a	 suitable	poly-U	
stretch	in	the	3’UTR	of	E2F1	mRNA	and	performed	an	RNA	pull-down	experiment	using	
both	 a	wild-type	 RNA	 probe	 containing	 the	 poly-U	 stretch	 and	 a	mutated	 RNA	 probe	
where	 the	 poly-U	 stretch	 had	 been	 interrupted.	 As	 positive	 control,	 I	 used	 the	 probe	
containing	the	poly-U	stretch	of	H1X	3’UTR,	which	we	previously	observed	to	be	bound	
by	 RALY	 109.	 The	 pulled-down	 proteins	 were	 then	 analyzed	 by	 Western	 blot.	
Interestingly,	RALY	was	captured	only	by	the	wild-type	sequence,	while	not	binding	the	
mutated	probe	(Fig.	13B).	On	the	contrary,	neither	Tubulin	nor	Actinin	were	observed	to	
be	captured	by	either	of	the	probes,	excluding	the	possibility	of	unspecific	bindings	(Fig.	
13B).	As	expected,	the	positive	control	pulled-down	RALY	from	the	cell	lysate	(Fig.	13B).	
These	results	demonstrate	that	RALY	directly	binds	E2F1	mRNA.	
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Figure	 13.	 RALY	 binds	 E2F1	 mRNA	 on	 a	 poly-U	 stretch	 in	 the	 3’UTR.	 (A)	 qRT-PCR	 was	 used	 to	
compare	 the	 indicated	 mRNAs	 isolated	 upon	 UV-crosslinked	 RALY	 immunoprecipitation	 with	 RNA	
recovered	after	immunoprecipitation	with	IgG.	E2F1	mRNA	is	enriched	in	RALY-containing	RNPs.		The	
relative	 abundance	was	 compared	 to	 the	 10%	of	 input.	 The	 experiments	were	 performed	 at	 least	
three	 times.	 Bars	 represent	 means	 ±	 S.D.	 P-value	 was	 calculated	 comparing	 the	 amount	 of	 each	
mRNA	with	the	amount	of	GAPDH	using	an	unpaired	two	tailed	t-test	(*P<0.05).	(B)	Sequences	of	the	
biotinylated	wild-type	and	mutant	E2F1	3’UTR	probes,	and	of	the	positive	control	H1FX	3’UTR	probe.	
(C)	HeLa	cells	total	protein	extract	was	incubated	with	either	E2F1	wild-type	or	mutant	biotinylated	
RNA	probes	(50	pmol)	and	captured	by	streptavidin	beads.	H1X	3’UTR	biotinylated	probe	was	used	as	
positive	CTRL,	as	described	by	Rossi	and	colleagues	109.	Western	blot	of	RNA-bound	proteins	shows	
the	positive	in	vitro	interaction	of	RALY	with	the	wild-type	poly-U	sequence,	but	not	with	the	mutant	
probe.	 Immunoblotting	 with	 anti-Actinin	 and	 anti-Tubulin	 served	 as	 negative	 control.	 The	 graph	
shows	the	mean	values	of	three	independent	experiments.	Bars	represent	mean	±	S.D.	P-value	was	
calculated	by	unpaired	two-tailed	t-test	(***P	<	0.001).	
Since	the	3’UTR	of	transcripts	is	often	targeted	by	trans-acting	factors	to	determine	the	
fate	of	the	mRNA,	I	decided	to	investigate	a	possible	regulatory	activity	of	RALY	on	E2F1	
mRNA	 at	 the	 post-transcriptional	 level.	 In	 the	 range	 of	 possible	 post-transcriptional	
modifications,	I	analyzed	transcript	stability	since	other	members	of	the	hnRNP	family,	in	
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particular	the	hnRNP-C	that	with	RALY	shares	a	high	similarity	in	the	RRM,	are	described	
to	 regulate	 the	 stability	 of	 specific	 transcripts	 56,59,64.	 To	 investigate	 a	 possible	 similar	
function	of	RALY,	 I	analyzed	the	stability	of	E2F1	mRNA	 in	absence	of	RALY.	HeLa	cells	
transfected	with	either	si-CTRL	or	si-RALY	for	72	hours	were	treated	with	ActD	(5	μg/ml)	
for	different	periods	of	time	to	prevent	new	RNA	synthesis.	The	stability	over	time	of	the	
remaining	RNAs	was	analyzed	by	qRT-PCR.	As	depicted	in	Fig.	14A,	the	stability	of	E2F1	
in	RALY	silenced	HeLa	cells	was	measured	to	be	 lower	over	time,	compared	to	si-CTRL	
cells,	with	a	half-life	of	7.64±1.32	hours.	 In	 si-CTRL	cells,	E2F1	mRNA	was	 found	 to	be	
stable	 over	 the	 9	 hours	 analyzed	 time-frame,	 and	 its	 half-life	 could	 not	 be	 reliably	
calculated.	As	 a	 control,	 I	 used	 the	mRNA	 coding	 for	GAPDH,	which	 is	 not	 a	 target	 of	
RALY	 (Fig.	 13A)	 and	 which	 was	 described	 to	 be	 suitable	 for	 assessing	 general	 mRNA	
stability	155.	GAPDH	mRNA	was	found	to	be	stable	over	9	hours	 in	both	si-CTRL	and	si-
RALY	transfected	cells	(Fig.	14B).		
Taken	together,	these	results	show	that	in	absence	of	RALY	the	stability	of	E2F1	mRNA	is	
reduced.	As	 a	 consequence,	both	E2F1	mRNA	and	protein	are	downregulated	 in	RALY	
silenced	cells.		
3.8	 	 RALY	 has	 a	 positive	 effect	 on	 E2F1	mRNA	and	many	 of	 its	
targets	
In	principle,	only	a	fraction	of	the	misregulated	mRNAs	detected	by	microarray	analysis	
was	affected	 in	 its	expression	consequently	to	the	 loss	of	direct	contact	with	RALY.	To	
preliminarily	 investigate	 the	 global	 effect	 of	 the	 downregulation	 of	 RALY	 on	 its	 target	
mRNAs,	 I	 intersected	 the	 microarray	 list	 of	 differentially	 expressed	 genes	 upon	 RALY	
downregulation	with	the	list	of	RALY	targets	identified	by	RIP-seq	in	MCF7	cells	by	Rossi	
and	colleagues	109.	From	this	merge,	considering	the	provenience	of	the	data	from	two	
different	cell	 lines,	 I	obtained	193	upregulated	genes	and	359	downregulated	genes	of	
the	microarray	 that	were	also	detected	as	direct	RALY	 targets	 (Fig.	 14C).	 Interestingly,	
there	 was	 an	 increased	 frequency	 of	 RALY	 RNA	 targets	 among	 genes	 downregulated	
upon	RALY	silencing	(34.1%	vs	21%,	P-value	1.3e-10)	suggesting	that	the	loss	of	a	direct	
RALY-mRNA	interaction	mediates	the	downregulation	of	the	target	transcript	(Fig.	14C).	
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This	analysis,	even	though	preliminar,	suggests	a	positive	effect	of	RALY	in	determining	
the	fate	of	its	target	RNAs.		
	
Figure	14.	 RALY	stabilizes	E2F1	mRNA.	 (A-B)	HeLa	cells	were	transfected	either	with	si-RALY	or	si-
CTRL	for	72	hours	and	successively	treated	with	ActD	(5	μg/ml)	 for	0,	2,	4,	6	or	9	hours.	Total	RNA	
was	extracted,	analyzed	through	qRT-PCR	and	normalized	on	ACTB.	(A)	E2F1	mRNA	was	detected	to	
be	 less	 stable	 in	 si-RALY	 transfected	 cells	 compared	 to	 si-CTRL	 cells.	E2F1	mRNA	was	measured	 to	
have	a	half-life	of	7.64±1.32	hours	in	si-RALY	cells,	while	being	stable	for	over	9	hours	in	si-CTRL	cells.	
(B)	On	 the	 contrary,	GAPDH	mRNA	 showed	 to	 be	 comparably	 stable	 between	 si-RALY	 and	 si-CTRL	
transfected	 cells.	 (C)	 Intersection	 between	 the	 lists	 of	 si-RALY	 up	 (blue)	 or	 down	 (red)	 regulated	
genes	 in	 HeLa	 cells	 and	 the	 list	 of	 RALY	 RIP-seq	 targets	 previously	 identified	 in	 MCF7	 cells	
(DEG=Differentially	 Expressed	Gene)	 109.	 The	percentage	of	 overlap	with	 respect	 to	 the	number	of	
DEGs	is	displayed	beside	the	corresponding	bar.	Although	the	intersection	could	be	affected	by	cell	
line	 differences,	 the	 increased	 frequency	 of	 RALY	 RNA	 targets	 among	 genes	 downregulated	 upon	
RALY	 silencing	 suggests	 that	 the	 loss	 of	 a	 direct	 RALY-mRNA	 interaction	 is	 associated	 with	 the	
downregulation	of	 the	 target.	Following	 the	analysis	of	E2F1	mRNA	 (A),	 it	 is	 tempting	 to	 suggest	a	
positive	role	of	RALY	in	determining	the	fate	of	its	target	mRNAs.	
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3.9		The	absence	of	RALY	impairs	cell	proliferation	
To	confirm	the	importance	of	RALY	in	the	regulation	of	cellular	physiology,	 I	measured	
the	proliferation	rate	and	cell	cycle	distribution	of	RALY	KO	cells.	I	used	the	CRISPR/Cas9	
engineered	 cells	 to	 have	 a	 stable	 RALY	 negative	 cell	 population.	 In	 fact,	 siRNA	
transfected	cells	showed	a	gradual	recovery	of	RALY	expression	and	a	slow	take-over	of	
not-silenced	 cells	 after	 5	 days	 from	 transfection,	 which	 would	 have	 made	 the	
measurement	 not	 reliable	 (Fig.	 15A).	 First,	 I	measured	 E2F1	protein	 expression	 in	 the	
RALY	 KO	 cell	model,	 confirming	 the	 downregulation	 of	 E2F1	 (Fig.	 15B).	 Successively,	 I	
compared	the	proliferation	of	RALY	KO	and	control	cells	with	two	different	approaches:	
one	based	on	the	count	of	cells	through	fluorescence	(Fig.	15C),	another	based	on	the	
xCELLigence	Real	Time	Cell	Analysis	platform	(Fig.	15D).	The	latter	measures	the	electric	
impedance	of	the	wells	where	the	cells	are	plated,	which	will	increase	proportionally	to	
the	surface	occupied	by	 the	cells.	 Interestingly,	both	 the	approaches	 showed	a	 slower	
cell	 growth	 in	 the	 RALY	 KO	 cell	 population	 compared	 to	 EV	 control	 cells.	 In	 the	
xCELLigence	experiment,	RALY	KO	cells	did	not	reach	the	confluency	plateau	during	the	
62	 hours	 analyzed	 time	 frame,	 while	 EV	 control	 cells	 stopped	 growing	 because	 of	
confluency	 around	45	hours	 after	 seeding.	 RALY	 KO	 cells	 do	 not	 show	an	 exponential	
grow	phase,	presenting	instead	a	linear	growth.		
To	measure	 the	 distribution	 of	 RALY	 KO	 cells	 through	 the	 different	 phases	 of	 the	 cell	
cycle,	I	used	an	approach	based	on	fluorescence	microscopy.	I	cultured	the	cells	for	24	
hours	and	I	 incubated	them	with	5-Ethynyl	deoxyuridine	(5EdU),	a	thymidine	analogue	
that	 is	 incorporated	 in	 DNA	 during	 cell	 replication.	 Successively,	 I	 stained	 5EdU	 with	
5FAM	 as	 for	 the	 RNA	 synthesis	 assay	 and	 I	 quantified	 the	 DNA	 content	 of	 every	 cell	
through	 the	 High	 Content	 Imaging	 System.	 Based	 on	 the	 work	 done	 by	 Massey	 and	
colleagues,	 I	 analyzed	 the	 cells	 to	 sort	 them	 in	 the	 different	 phases	 of	 the	 cell	 cycle	
depending	on	their	DNA	content	156.	As	shown	in	Fig.	15E,	RALY	KO	cells	were	detected	
to	be	enriched	in	the	G1	phase	and	in	parallel	less	present	in	the	S	and	G2	phases	of	the	
cell	 cycle	 compared	 to	 EV	 control	 cells.	 These	 results	 are	 in	 accordance	 with	 the	
downregulation	 of	 numerous	 proliferation	 and	 cell	 cycle	 related	 genes	 in	 cells	 where	
RALY	was	silenced	and	finally	confirm	RALY	as	an	important	player	 in	the	regulation	of	
cell	proliferation.		
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Figure	15.	 The	absence	of	RALY	 impairs	 cell	 proliferation.	 (A)	HeLa	cells	were	 transfected	with	si-
RALY	 and	 si-CTRL	 and	 then	 fixed	 and	 processed	 for	 immunofluorescence	 after	 different	 days	 post	
transfection.	 RALY	 was	 stained	 with	 an	 anti-RALY	 antibody	 and	 an	 intensity	 threshold	 was	 set	 to	
discriminate	 the	 RALY	 downregulated	 cells.	 The	 population	 of	 not	 RALY-downregulated	 cells	
gradually	 increases	 from	 5	 days	 after	 transfection.	 The	 graph	 shows	 the	 mean	 values	 of	 three	
independent	 experiments.	 Bars	 represent	mean	 ±	 S.D.	 (B)	 Total	 RALY	 KO	 and	 EV	 cell	 lysates	were	
subjected	to	SDS/PAGE	and	Western	blot	with	the	indicated	antibodies.	The	bands	were	analyzed	by	
densitometry	 analysis.	 E2F1	 is	 downregulated	 in	 RALY	 KO	 cells	 compared	 to	 controls.	 The	 graph	
shows	the	mean	values	of	three	independent	experiments.	Bars	represent	mean	±	S.D.	P-value	was	
calculated	by	unpaired	two-tailed	t-test	(**P	<	0.01).	(C)	EV	and	RALY	KO	cells	were	fixed	and	stained	
with	 DAPI	 different	 days	 after	 seeding.	 The	 number	 of	 cells	 was	 measured	 counting	 the	 nuclei	
through	the	High	Content	Imaging	System,	and	every	measurement	was	normalized	on	the	number	
of	 cells	 present	 in	 the	wells	 at	Day	1.	 RALY	KO	 cells	 grow	 slower	 compared	 to	 EV	 cells.	 The	 graph	
shows	 the	mean	values	of	 three	 independent	experiments.	Bars	 represent	mean	±	S.D.	 (D)	EV	and	
RALY	 KO	 cells	 were	 seeded	 in	 a	 xCELLigence	 E-plate	 and	 cell	 proliferation	 was	 monitored	 for	 62	
hours.	 All	 the	 values	 were	 normalized	 on	 the	 impedance	 detected	 at	 10	 hours	 post	 seeding,	
considered	as	the	moment	where	all	the	cells	were	attached	to	the	surface	and	started	to	proliferate.	
RALY	 KO	 cells	 grow	 slower	 than	 EV	 control	 cells.	 The	 graph	 shows	 the	 mean	 values	 of	 three	
experimental	 replicas.	 The	 experiment	 was	 repeated	 three	 times,	 giving	 the	 same	 output.	 Bars	
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represent	mean	±	S.D.	(E)	EV	and	RALY	KO	cells	were	cultured	for	24	hours	and	then	incubated	for	1	
hour	with	5EdU	to	stain	newly	synthesized	DNA.	5EdU	was	then	stained	with	5FAM	and	the	amount	
of	DNA	in	each	cell	was	measured	through	the	High	Content	Imaging	System,	successively	sorting	the	
cells	 in	the	different	phases	of	the	cell	cycle.	RALY	KO	cells	tend	to	stall	 in	the	G1	phase	of	the	cell	
cycle,	 with	 a	 consequent	 lower	 percentage	 of	 cells	 in	 the	 S	 and	 G2	 phases.	 The	 graph	 shows	 the	
mean	values	of	three	independent	experiments.	Bars	represent	mean	±	S.D.	P-value	was	calculated	
by	unpaired	two-tailed	t-test	(***P	<	0.001).		
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4. Discussion	
The	 aim	 of	my	 thesis	 was	 to	 better	 characterize	 the	 role	 of	 the	 hnRNP	 RALY	 in	 RNA	
metabolism.	In	fact,	RALY	was	described	to	bind	numerous	mRNAs	and	to	regulate	the	
expression	of	specific	targets	109,	but	its	function	was	still	elusive.	I	showed	RALY	to	be	
differently	associated	to	distinct	nuclear	 fractions,	possibly	to	exert	multiple	 functions,	
and	 to	 regulate	 the	 expression	 of	 several	 transcription-	 and	 proliferation-	 promoting	
factors,	ultimately	affecting	global	transcription	and	cell	proliferation.		Given	the	results	
of	 the	 microarray	 analysis,	 I	 focused	 on	 the	 role	 of	 RALY	 in	 the	 post-transcriptional	
regulation	of	 the	proliferation	marker	E2F1.	 I	 showed	RALY	to	promote	the	stability	of	
E2F1	mRNA,	eventually	determining	the	amount	of	E2F1	protein	inside	the	cells.		
	
RALY	contains	an	RRM	at	the	N-terminal	domain,	two	putative	NLSs,	and	an	RGG	in	the	
C-terminal	 region	 105,114.	 My	 results	 demonstrate	 that	 RALY	 interacts	 with	
transcriptionally	active	 chromatin	and	 that	 this	 association	 is	partially	 abrogated	upon	
RNA	degradation	(Fig.	1C).	Based	on	my	analyses,	I	propose	that	the	association	of	RALY	
with	 transcriptionally	 active	 chromatin	 is	 mediated	 by	 two	 types	 of	 interaction:	 one	
RNA-dependent	 through	 the	RRM	domain,	hypothetically	 to	bind	and	process	RNAs	 in	
synergy	with	other	 factors;	one	RNA-independent	mediated	by	 the	C-terminal	domain	
(Fig.	 2D).	 Interestingly,	 the	 fragment	 of	 RALY	 involved	 in	 the	 RNA-independent	
interaction	(amino	acids	143-306)	contains	a	region	similar	to	a	basic-leucine	zipper-like	
motif	(bZLM)	presented	by	hnRNP-C	and	typical	of	DNA-binding	proteins,	more	precisely	
located	 in	between	amino	acids	146-214	 66,114.	Since	 the	construct	containing	only	 the	
RGG	domain	was	not	 found	on	 transcriptionally	 active	 chromatin,	 I	 conclude	 that	 this	
bZLM	is	necessary	for	the	RNA-independent	association	of	RALY	with	active	chromatin.	
This	interaction	might	allow	RALY	to	function	as	a	transcriptional	co-factor,	binding	DNA,	
but	could	also	serve	to	anchor	RALY	on	chromatin	to	allow	its	N-terminal	RRM	domain	to	
contact	 newly	 synthesized	 transcripts	 114.	 In	 fact,	 different	 RBPs,	 some	 of	 which	
interacting	with	RALY,	can	associate	with	chromatin	to	have	access	to	newly	synthesized	
RNAs	 69,75,100,157.	Further	experiments	will	better	characterize	 the	binding	properties	of	
this	predicted	bZLM	domain	and	the	function	of	the	two	different	associations	of	RALY	
to	transcriptionally	active	chromatin.	
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To	 gain	 more	 information	 about	 the	 cellular	 distribution	 of	 RALY,	 I	 analyzed	 the	
localization	of	the	RBP	FUS,	classified	as	hnRNP-P2,	which	was	recently	studied	by	Yang	
and	colleagues	(Fig.	1A)	94,100.	FUS	is	a	well	studied	RBP	because	of	its	association	with	
multiple	diseases,	in	particular	affecting	the	nervous	system,	playing	different	biological	
functions,	 including	 transcription	 regulation,	 RNA	 biogenesis	 and	 post-transcriptional	
modification	 99,158,159.	 FUS	 is	 mainly	 present	 in	 the	 nuclear-soluble	 and	 the	
transcriptionally	 active	 chromatin	 fractions,	 where	 it	 was	 described	 to	 have	 a	
transcriptional	 control	 function	 100.	 In	 particular,	 RALY	 and	 FUS	 share	 the	 association	
with	transcriptionally	active	chromatin.	However,	the	association	of	FUS	with	chromatin	
was	 described	 to	 be	 strictly	 RNA	 dependent,	 while	 a	 portion	 of	 RALY	 persists	 on	
chromatin	even	in	absence	of	RNA,	suggesting	different	molecular	functions	of	the	two	
RBPs.	 Considering	 that	 FUS	 was	 identified	 as	 an	 interactor	 of	 RALY	 through	 mass	
spectrometry	and	that	RALY	was	characterized	as	a	transcriptional	co-factor,	this	shared	
association	 opens	 the	 possibility	 for	 a	 co-operative	 function	 of	 the	 two	 hnRNPs	 in	
transcriptional	control,	but	also	in	RNA	maturation	105,114.		
The	 association	 of	 RALY	 with	 transcriptionally	 inactive	 chromatin	 is	 not	 affected	 by	
RNase	 treatment,	 leaving	 this	 interaction	 uncharacterized.	 Further	 experiments	 are	
needed	to	understand	the	biological	function	of	this	relationship.		
	
RALY	 showed	 a	 partial	 RNA-dependence	 in	 the	 interaction	with	 chromatin	when	 RNA	
was	 degraded	 in	 vitro.	 In	 vivo,	 the	 presence	 of	 RNA	 on	 chromatin	 is	 mainly	 due	 to	
ongoing	transcription	and	the	 inhibition	of	RNA	synthesis	might	 lead	to	changes	 in	the	
association	 of	 RBPs	 with	 chromatin.	 The	 treatment	 with	 Actinomycin	 D	 induced	 a	
progressive	 delocalization	 of	 RALY	 from	 the	 nucleus,	 more	 specifically	 from	
transcriptionally	active	chromatin,	 to	 the	cytoplasm,	 suggesting	 that	 the	 interaction	of	
RALY	with	this	fraction	of	chromatin	requires	the	active	synthesis	of	new	transcripts	(Fig.	
3B	and	3C,	Fig.	4A).	The	block	of	transcription	might	abrogate	the	dynamic	recruitment	
of	 RALY	 on	 chromatin	 and	 on	 newly	 synthesized	 RNAs,	 disrupting	 the	 existing	
interactions	 and	 preventing	 the	 formation	 of	 new	 associations.	 If	 the	 RNA-dependent	
and	 -independent	 interactions	 are	 differentially	 affected	 by	 the	 block	 of	 transcription	
remains	to	be	elucidated.		
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Given	 the	 strong	 effect	 that	 the	 block	 of	 transcription	 had	 on	 RALY	 localization,	 I	
investigated	 if	 the	reverse	relationship	was	also	standing,	namely	the	absence	of	RALY	
affecting	 transcription.	 The	 downregulation	 of	 RALY	 induced	 a	 global	 decrease	 of	
RNAPII-dependent	transcription	(Fig.	5-7),	without	affecting	RNAPII	dynamics	(Fig.	9).	To	
explain	 the	 decrease	 of	 RNA	 synthesis,	 I	 analyzed	 the	 transcriptome	 profile	 of	 RALY	
silenced	HeLa	cells.	In	fact,	being	RALY	an	RNA-binding	protein,	it	was	plausible	that	the	
effects	 on	 cell	 physiology	 upon	 RALY	 downregulation	were	 due	 to	 a	misregulation	 of	
RALY	 mRNA	 targets.	 The	 microarray	 experiment	 detected	 an	 altered	 expression	 of	
several	transcription-	and	cell	cycle-related	genes	(Table	2	 in	Appendix),	 in	accordance	
with	 the	 decreased	 RNA	 transcription	 described	 above	 and	 the	 misregulation	 of	 cell	
cycle	previously	described	by	Rossi	and	colleagues	109.	I	proceeded	validating	by	qRT-PCR	
the	mRNA	expression	of	factors	involved	in	the	two	processes.	
Regarding	 the	decreased	 transcriptional	activity	of	RALY	 silenced	cells,	 I	measured	 the	
mRNA	expression	of	different	transcription	promoting	factors,	such	as	CCNT1,	the	Cyclin	
subunit	of	the	Positive	Transcription	Elongation	Factor	b	(P-TEFb),	a	complex	responsible	
for	the	release	of	RNAPII	from	the	promoter-proximal	pausing	and	for	the	activation	of	
RNAPII	 productive	 elongation;	GTF2A1	 and	GTF2E2,	 subunits	 of	 general	 transcription	
factors	 involved	 in	 transcription	 initiation,	 and	 ELL2,	 a	 member	 of	 the	 transcription-
promoting	 Super	 Elongation	 Complex	 (Fig.	 11A)	 2,21,140,141,160.	 In	 addition,	 the	 two	
subunits	 of	 the	 Facilitating	 Transcription	 (FACT)	 complex,	 SUPT16H	 and	 SSRP1,	 were	
found	to	be	downregulated	at	the	mRNA	level	in	RALY	silenced	cells	(Fig.	11A).	The	FACT	
complex	 was	 described	 to	 associate	 with	 active	 RNAPII	 and	 to	 promote	 nucleosome	
disassembly	 in	 order	 to	 facilitate	 transcription	 143,144,161.	 The	 downregulation	 of	 these	
transcription-promoting	factors	in	RALY	silenced	cells,	together	with	other	transcription-
related	 targets	 detected	 by	microarray	 analysis,	 possibly	 explains	 the	 observed	 global	
decrease	in	RNA	synthesis.	
Regarding	cell	cycle	progression,	I	validated	the	mRNA	expression	of	different	cell	cycle-	
related	 factors,	 such	 as	 CCNB1,	 CCNB2	 and	 CDK1,	 which	 together	 drive	 the	 G2/M	
transition;	CCNE1	 and	CCNE2,	 two	 regulators	 of	 the	 entry	 in	 S	 phase,	 and	CDC25A,	 a	
phosphatase	 involved	 in	both	 the	 S-phase	entry	 and	 the	G2-phase	 transition	 (Fig.	 2A)	
137–139.	All	the	targets	resulted	to	be	significantly	downregulated	in	RALY	silenced	cells.	
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In	order	to	improve	the	functional	characterization	of	the	deregulated	transcripts	upon	
RALY	silencing,	 I	performed	gene	set	enrichment	analysis	 (GSEA)	over	the	collection	of	
“Hallmark”	 annotated	 gene	 sets	 provided	 by	 the	 Molecular	 Signatures	 Database	
(MSigDB)	147.	The	analysis	revealed	an	enrichment	of	cell	cycle-related	targets	of	the	E2F	
family	in	the	downregulated	genes	upon	RALY	silencing	(Fig.	12A).	The	family	of	the	E2F	
transcription	factors	comprises	eight	members	(E2F1-8)	that	regulate	cell	physiology	by	
either	 promoting	 or	 repressing	 cell	 cycle	 progression.	 A	 tight	 equilibrium	 stands	
between	these	two	“factions”	and	the	most	abundant	one	will	in	the	end	decide	the	fate	
of	the	cell	146.	Interestingly,	all	the	cell	cycle	promoting	E2Fs	(E2F1-3)	were	found	to	be	
downregulated	 by	 microarray	 analysis	 upon	 RALY	 silencing	 (Table	 2	 in	 Appendix).	 I	
focused	 on	 E2F1,	 a	well-known	marker	 of	 cell	 proliferation	 and	 promoter	 of	 S-phase,	
which	 can	 also	 induce	 apoptosis	 through	 different	 p53-dependent	 and	 -independent	
mechanisms	 162–164.	 Due	 to	 this	 dichotomous	 role	 as	 proliferation-	 and	 apoptosis-
promoting	factor,	E2F1	was	described	as	both	oncogene	and	tumor	suppressor	gene	165.	
The	 overexpression	 of	 E2F1	 has	 been	 reported	 in	 numerous	 types	 of	 cancer,	 and	 its	
ectopic	 expression	 was	 described	 to	 drive	 S-phase	 entry	 in	 quiescent	 cells	 and	
hyperplasia	 150,151.	 I	 showed	 that	RALY	 interacts	with	and	 regulates	 the	 stability	of	 the	
mRNA	coding	for	E2F1,	determining	the	expression	of	E2F1	protein	(Fig.	12C-D,	Fig.	13,	
Fig.	14A).	 Inside	the	cell,	E2F1,	 together	with	 its	activating	partner	transcription	factor	
DP1	(TFDP1),	is	normally	kept	in	an	inactivated	state	by	the	Retinoblastoma	protein	(Rb)	
and	 is	 released	 at	 the	 G1/S	 phase	 transition	 after	 the	 phosphorylation	 of	 Rb	 by	 the	
Cyclin	D-CDK4/6	dimers.	The	E2F1-TFDP1	complex	will	induce	the	expression	of	S-phase	
promoting	 factors,	 as	 Cyclin	 E1	 and	 E2	 (CCNE).	 In	 a	 positive	 feedback	 loop,	 CCNE	will	
bind	its	partner	CDK2	to	further	phosphorylate	Rb,	consequently	increasing	the	levels	of	
free	E2F1-TFDP1	complexes	166–168.	At	this	point,	the	cell	is	strongly	directed	towards	S-
phase.	Interestingly,	an	excess	of	CCNE	was	observed	to	promote	G1	progression	and	a	
CCNE	 upregulation	 was	 found	 in	 different	 cancers,	 correlating	 with	 poor	 prognosis	
162,169,170.	 A	 decreased	 expression	 of	 E2F1	 therefore	 de-potentiates	 the	 G1/S	 phase	
transition,	 lowering	 the	expression	of	proliferation	promoting	genes,	as	CCNE	 168.	As	a	
consequence,	 I	 observed	 a	 lower	 expression	 of	 direct	 targets	 of	 E2F1	 transcriptional	
control	activity,	as	 in	 fact	CCNE1	and	CCNE2,	and	CDC25A,	CDK1	and	CCNB1	 (Fig.	11A)	
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167,168,171,172.	 In	addition,	also	TFDP1	mRNA	was	 found	to	be	downregulated	upon	RALY	
silencing	 (Fig.	 11A),	 suggesting	a	 further	decreased	activity	of	all	 the	E2F	 transcription	
factors.	
Except	CDC25A,	 the	 other	mRNA	 targets	were	 detected	 in	 the	RIP-seq	 experiment	 on	
MCF7	 cells	 performed	 by	 Rossi	 and	 colleagues	 109.	 Although	 these	 direct	 interactions	
were	not	validated	in	HeLa	cells,	no	adverse	effects	were	observed	in	their	stability	upon	
RALY	downregulation	(data	not	shown).	Therefore,	I	cannot	exclude	that,	beyond	E2F1	
downregulation,	 also	 the	 lost	 direct	 interaction	 with	 RALY	 somehow	 affected	 their	
expression.	 In	 fact,	 even	 though	 preliminarily,	 I	 observed	 that	 the	 loss	 of	 direct	
interaction	 RALY-mRNA	 is	 often	 associated	with	 the	 downregulation	 of	 the	 transcript,	
suggesting	a	general	positive	 role	of	RALY	 in	determining	 the	 fate	of	 its	mRNA	targets	
(Fig.	14C).	
	
To	confirm	the	effects	of	the	downregulation	of	RALY	on	cell	growth,	I	analyzed	both	cell	
proliferation	 and	 cell	 cycle	 distribution	 of	 RALY	 KO	 cells.	 In	 absence	 of	 RALY,	 cell	
proliferation	proceeds	slower	and	the	cells	 tend	to	accumulate	 in	 the	G1	phase	of	 the	
cell	cycle	compared	to	control	cells	(Fig.	15C-E).	
	
The	observation	of	the	downregulation	of	E2F1	upon	RALY	silencing,	together	with	the	
lower	 expression	 of	 numerous	 transcription-	 and	 proliferation-promoting	 factors	 (Fig.	
11A	and	Table	2	 in	Appendix),	 is	 in	accordance	with	the	observed	diminished	RNAPII-
dependent	 transcription,	 decreased	 cell	 proliferation	 and	 misregulated	 cell	 cycle	
progression.	In	this	picture,	these	processes	are	directly	impaired	by	the	downregulation	
of	 the	 respective	 promoting	 factors	 in	 response	 to	 RALY	 silencing,	 and	 also	mutually	
affect	 each	 other.	 Therefore,	 I	 propose	 RALY	 as	 a	 novel	 indirect	 regulator	 of	
transcription	and	cell	proliferation.	
	
To	bring	 the	analysis	of	 the	 interaction	between	RALY	and	E2F1	 to	 a	higher	 level,	 the	
ENCODE	project	found	E2F1	to	interact	with	the	promoter	of	RALY,	making	tempting	to	
consider	 RALY	 as	 a	 bona	 fide	 target	 of	 E2F1.	 Furthermore,	 the	 cBioPortal	 for	 Cancer	
Genomics	 reported	 RALY	 and	 E2F1	 to	 be	 frequently	 co-amplified	 in	 tumours	 173.	 The	
colorectal	 adenocarcinoma	 was	 detected	 as	 the	 tumour	 type	 presenting	 the	 highest	
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number	of	co-amplification	events	of	RALY	and	E2F1	(31	out	of	212	analysed	patients).	
In	this	malignancy,	the	expression	of	the	two	genes	was	positively	correlated	(Pearson	
coefficient	 =	 0.7)	 173.	 This	 analysis	 intriguingly	 suggests	 the	 existence	 of	 a	 positive	
feedback	 loop	 where	 E2F1	 enhances	 the	 expression	 of	 RALY,	 which	 in	 turn	 stabilizes	
E2F1	mRNA.	However,	the	fact	that	RALY	and	E2F1	loci	are	located	close	to	each	other	
on	 chromosome	 20	 has	 to	 be	 taken	 into	 account.	 Further	 investigations	 will	 better	
clarify	the	relationship	between	E2F1	and	RALY.	
	
Considering	my	results,	pieces	have	been	added	to	the	understanding	of	the	biological	
functions	 of	 RALY,	 but	 different	 questions	 regarding	 the	molecular	 functions	 of	 RALY	
remain	unanswered.	Nevertheless,	an	involvement	of	RALY	in	the	3’end	processing	and	
termination	 can	 be	 hypothesized.	 In	 fact,	 Fasken	 and	 colleagues	 observed	 function	
homologies	 between	 the	 human	 RALY	 and	 the	 yeast	 protein	 Nab3,	 an	 RNA-binding	
protein	 involved	 in	 the	exosome-mediated	processing,	 termination	and	degradation	of	
non-coding	RNAs	(ncRNAs)	174.	Nab3	and	RALY	share	31%	of	sequence	homology	in	the	
RRM	and	a	certain	degree	of	similarity	also	in	the	C-terminal	region,	and	the	expression	
of	 RALY	 in	 Nab3	 negative	 cells	 rescued	 the	 thermosensitive	 yeast	 phenotype.	
Interestingly,	to	be	efficient,	both	the	proteins	needed	a	functional	RRM	174.	RALY	could	
be	involved	in	the	3’end	processing	also	of	coding	RNAs,	and	not	only	ncRNAs,	ultimately	
affecting	 RNA	 stability	 and	 biogenesis,	 but	 further	 experiments	 are	 needed	 to	 better	
elucidate	this	possibility.	
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5. Conclusion	and	Future	Perspectives	
Taken	 together,	 the	 results	of	my	PhD	project	better	define	 the	biology	of	 the	hnRNP	
RALY	inside	the	nucleus,	in	particular	highlighting	a	transcription-dependent	association	
with	transcriptionally	active	chromatin.	The	downregulation	of	RALY	induced	a	decrease	
of	 RNAPII-dependent	 transcription	 inside	 the	 nuclei	 and	 affected	 the	 expression	 of	
numerous	 transcription-	 and	 cell	 proliferation-	 promoting	 factors.	 As	 a	 consequence,	
RALY	KO	cells	show	a	slower	proliferation	and	a	stalling	in	the	G1	phase	of	the	cell	cycle	
compared	to	control	cells.	Specifically,	I	focused	on	the	transcription	factor	E2F1,	marker	
of	 proliferation	 and	 inducer	of	 apoptosis.	 I	 showed	 that	E2F1	 transcript	 is	 enriched	 in	
RALY-containing	ribonucleoparticles	and	that	the	levels	of	E2F1	protein	in	cells	silenced	
for	 RALY	 were	 reduced	 due	 to	 a	 diminished	 stability	 of	 E2F1	 mRNA.	 In	 addition,	 I	
propose	a	general	positive	effect	of	RALY	on	its	mRNA	targets.		
	
As	future	perspectives,	the	specific	functions	of	the	different	 interactions	of	RALY	with	
transcriptionally	 active	 chromatin	 will	 be	 investigated	 in	 more	 details.	 The	 bZLM-
dependent	 association	 paves	 the	 way	 for	 an	 in-depth	 study	 of	 RALY	 activity	 as	
transcriptional	 co-factor.	 It	 would	 be	 interesting	 to	 further	 characterize	 the	 possible	
DNA	 binding	 ability	 of	 RALY	 and,	 if	 successful,	 to	 successively	 identify	 a	 consensus	
sequence	recognized	by	RALY	bZLM	to	classify	target	DNA	sequences	and	to	understand	
the	 biological	 function	 of	 these	 interactions.	 With	 this	 study,	 it	 could	 be	 possible	 to	
attribute	a	direct	function	to	RALY	in	regulating	the	expression	of	part	of	its	targets.	
In	parallel,	it	would	be	also	fascinating	to	better	understand	the	function	of	the	nuclear-
soluble	pool	of	RALY.	In	fact,	RALY	localizes	in	this	fraction	both	in	a	RNA-dependent	and	
-independent	manner.	 In	 the	 nuclear-soluble	 fraction,	 the	 N-terminal	 RRM-containing	
fragment	 of	 RALY	 was	 affected	 by	 RNase	 A	 treatment,	 while	 the	 C-terminal	 domain	
maintained	its	localization	(Fig.	2).	It	is	reasonable	to	hypothesize	that	the	block	of	RNA	
synthesis	 only	 affects	 the	 pool	 of	 RALY	 directly	 interacting	 with	 RNA,	 while	 not	
disturbing	the	remaining	RALY	engaged	in	interactions	with	other	proteins,	for	example	
as	member	of	RNPs	or	different	protein	complexes.		
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Regarding	 the	 second	part	of	 the	project,	 it	would	be	 interesting	 to	better	 investigate	
the	role	of	RALY	in	respect	to	the	downregulated	genes	upon	its	silencing.	I	showed	how	
the	absence	of	RALY	determined	a	decreased	stability	of	E2F1	mRNA,	but	other	direct	
targets	 of	 RALY	 did	 not	 exhibit	 the	 same	 behavior.	 Being	 RBP-complexes	 very	
heterogeneous	and	dynamic	in	their	composition,	I	can	hypothesize	that	the	final	effect	
of	 the	direct	 interaction	RALY-mRNA	could	depend	on	the	partners	of	RALY	present	 in	
the	 complex.	 Alternatively,	 since	 RALY	 was	 proven	 to	 bind	 poly-U	 stretches,	
preferentially	 in	 the	 3’	 UTRs	 of	 transcripts,	 different	 poly-U	 stretches	 patterns	 could	
induce	RALY	to	push	the	mRNA	towards	alternative	fates	109.	It	would	be	also	interesting	
to	better	understand	if	the	stabilizing	effect	RALY	on	E2F1	mRNA	occurs	the	the	level	of	
the	nucleus	or	 the	 cytoplasm.	 Further	experiments	are	needed	 to	 find	 the	 solution	 to	
this	 puzzle	 and	 better	 characterize	 the	 inferred	 general	 positive	 effect	 of	 RALY	 on	 its	
mRNA	targets.	
6. Additional	Results	
6.1	RALY	and	Splicing		
During	my	PhD,	I	tried	to	better	characterize	the	involvement	of	RALY	in	the	process	of	
splicing.	Hereby	are	presented	the	results	I	obtained	exploiting	different	approaches	of	
investigation.	
	
RALY	was	previously	shown	as	a	member	of	 the	EJC	and	as	an	 interactor	of	 important	
splicing	 factors,	 such	 as	 U2AF2,	 RbFOX1	 and	 PRP19,	 but	 its	 downregulation	 did	 not	
affect	 splicing	 105,111,112,175.	 However,	 a	 proper	 characterization	 of	 RALY	 in	 relation	 to	
splicing	was	still	missing.	For	this	reason,	I	 investigated	the	involvement	of	RALY	in	the	
process	 of	 splicing,	 particularly	 focusing	 on	 splicing	 dynamics	 and	 efficiency	 in	 cells	
where	RALY	was	downregulated.		
The	study	of	the	involvement	of	RALY	in	pre-mRNA	splicing	was	carried	on	together	with	
the	analysis	of	RNAPII	elongation	rate	in	absence	of	RALY.	Following	the	“kinetic	model”	
in	 fact,	 an	 influence	 of	 RALY	 on	 RNAPII	 elongation	 speed	 could	 have	 resulted	 in	 an	
alteration	 of	 splicing.	 Furthermore,	 the	 linker	 histone	H1X,	 strongly	 downregulated	 in	
RALY	 silenced	 cells,	was	 proposed	 to	 participate	 to	 the	 regulation	 of	 RNAPII	 speed	 to	
allow	specific	splicing	events	109,133.		
As	 first	 parameter,	 the	 timing	 of	 splicing	 was	 analyzed.	 To	 compare	 splicing	 speed	
between	 si-CTRL	 and	 si-RALY	 transfected	 cells,	 I	 used	 an	 approach	 similar	 to	 the	
measurement	of	RNAPII	elongation	rate	(Fig.	9).	In	addition	to	the	exon-intron	spanning	
primers	to	detect	the	transcription	of	specific	genomic	areas,	I	used	primers	to	identify	
splicing	events:	the	forward	primer	was	located	in	an	exon,	while	the	reverse	primer	was	
designed	 in	 the	 +1	 downstream	 intron.	 The	 qRT-PCR	 would	 therefore	 amplify	 the	
sequence	 only	 when	 the	 exon	 and	 the	 +1-intron	 are	 closer,	 meaning	 when	 splicing	
occurred	to	extrude	the	intron	immediately	downstream	to	the	selected	exon.	The	qRT-
PCR	Ct	value	where	the	spliced	transcript	becomes	detectable	can	be	compared	with	the	
time	taken	by	RNAPII	to	reach	that	specific	exon,	eventually	obtaining	the	time	took	by	
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the	spliceosome	to	extrude	the	+1	intron.	A	representative	scheme	of	the	technique	is	
depicted	in	Fig.	16.	
	
Figure	16.	Measurement	of	splicing	speed.	RNAPII-dependent	transcription	is	blocked	by	treatment	
with	 DRB	 (100	 μM)	 for	 3	 hours	 and	 synchronously	 re-activated	 by	 incubation	 of	 the	 cells	 in	 fresh	
medium.	 After	 re-activation,	 RNAPII	 starts	 again	 to	 transcribe	 genes.	 By	 extracting	 total	 RNA	 at	
different	times	after	re-activation	is	possible	to	detect	the	occurrence	of	splicing	events	through	qRT-
PCR	using	exon	-	+1-intron	primers	on	long	genes.	The	procedure	is	described	in	details	by	Singh	and	
Padgett	134.	
In	 literature,	 splicing	 was	 described	 to	 occur	 in	 a	 10	 minutes	 time	 window	 after	 the	
transcription	of	the	acceptor	splice	site	of	the	downstream	exon	134.	In	both	si-CTRL	and	
si-RALY	 HeLa	 cells,	 the	 splicing	 of	 the	 selected	 introns	 in	 the	 genes	OPA1	 and	 ITPR1	
occurred	 in	 this	 time	frame,	suggesting	 that	 the	timing	of	splicing	was	not	affected	by	
the	 silencing	 of	 RALY	 (Fig.	 17A	 and	 B).	 These	 results	 are	 still	 preliminary.	 Further	
measurements	of	the	splicing	speed	in	other	genes	and	especially	 in	RALY	RNA	targets	
will	 better	 define	 any	 involvement	 of	 RALY	 in	 splicing	 dynamics.	 More	 sensitive	
techniques	could	offer	a	more	precise	characterization	of	splicing	dynamics	 in	absence	
of	RALY.	
	 67	
	
	
Figure		17.	Analysis	of	the	speed	of	splicing	upon	RALY	silencing.	(A-B)	HeLa	cells	transfected	either	
with	si-RALY	or	si-CTRL	for	72	hours	were	treated	with	DRB	(100	μM)	for	3	hours.	After	washing	with	
PBS,	 the	 cells	 were	 incubated	 in	 DMEM	 to	 recover	 transcription.	 Successively,	 total	 RNA	 was	
collected	at	5	minute	 intervals.	qRT-PCR	with	different	exon-intron	and	exon-	+1-intron	primers	of	
ITPR1	allowed	the	observation	of	 the	splicing	 timing	of	 ITPR1	 intron	3	and	4	 (left	and	right	graphs,	
respectively).	The	pre-mRNA	expression	values	are	plotted	relative	to	the	expression	level	of	the	no	
DRB	treatment	control,	which	is	set	to	1	in	all	experiments.	RALY	does	not	impair	splicing	timing.	All	
the	graphs	of	the	figure	show	the	mean	of	three	independent	experiments	±	S.D.		
	
Next,	I	analyzed	the	efficiency	of	splicing	in	RALY	downregulated	HeLa	cells.	To	this	aim,	I	
calculated	the	ratio	between	the	mRNA	and	the	pre-mRNA	forms	of	different	transcripts	
by	 qRT-PCR	 (Fig.	 18A).	 To	 perform	 a	 more	 detailed	 analysis,	 the	 analyzed	 targets	
comprised	 both	 U2	 and	 U12	 introns.	 The	 minor	 spliceosome	 spliced	 introns	 were	
identified	using	the	U12DB	and	the	Ensembles	online	databases	176,177.	 In	particular,	of	
the	analyzed	 transcripts,	ASCC2	was	detected	as	a	mRNA	 target	of	RALY	by	RIP-seq	 in	
MCF7	 cells,	 Thoc2	 was	 detected	 to	 be	 downregulated	 and	 CDK6	 and	 EVI5	 to	 be	
upregulated	by	microarray	analysis	in	HeLa	cells	silenced	for	RALY	(Table	2	in	Appendix).	
No	significant	differences	were	detected	between	the	constitutive	splicing	efficiencies	of	
si-CTRL	and	si-RALY	cells	for	all	the	analyzed	splicing	events	(Fig.	18B).		
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To	better	 investigate	the	possible	relationship	between	RALY	and	alternative	splicing,	 I	
successively	analyzed	the	splicing	pattern	of	CD44.	This	gene	presents	10	constant	exons	
and	 9	 clustered	 variable	 exons	 and,	 given	 its	 numerous	 isoforms,	 is	 considered	 as	 a	
reference	gene	for	alternative	splicing	(Fig.	18C)	178.	The	microarray	analysis	detected	an	
upregulation	of	CD44	 in	si-RALY	HeLa	cells,	and	this	behavior	was	validated	measuring	
the	 amount	 of	 three	 CD44	 constant	 exons	 by	 qRT-PCR	 and	 calculating	 the	 average	
expression	(Fig.	18D,	upper	panel).	Measuring	the	levels	of	different	variable	exons	and	
normalizing	them	on	the	average	expression	of	the	whole	gene,	the	alternative	splicing	
pattern	of	CD44	presented	some	significant	differences	in	si-RALY	compared	to	si-CTRL	
cells	(Fig.	18D,	lower	panel).		
	
Figure	 18.	 Analysis	 of	 the	 efficiency	 of	 splicing	 upon	 RALY	 silencing.	 (A)	 Representation	 of	 the	
measurement	of	splicing	efficiency	through	qRT-PCR.	(B)	HeLa	cells	were	transfected	either	with	si-
CTRL	 or	 si-RALY	 for	 72	 hours.	 Total	 RNA	was	 extracted	 and	 analyzed	 by	 qRT-PCR,	 normalizing	 the	
signals	on	GAPDH.	The	 ratio	between	the	spliced	 intron	and	 the	unspliced	 intron	signals	 in	 si-RALY	
cells	was	compared	to	si-CTRL	cells,	which	were	set	to	1.	The	downregulation	of	RALY	does	not	impair	
the	 splicing	 efficiency	 of	 U2	 nor	 U12	 introns.	 (C)	 Representation	 of	 the	 CD44	 gene,	 taken	 and	
modified	 from	 Jimeno-Gonzalez	et	 al.178.	 (D)	 HeLa	 cells	were	 transfected	 either	with	 si-CTRL	 or	 si-
RALY	 for	 72	 hours.	 Total	 RNA	was	 extracted	 and	 analyzed	 by	 qRT-PCR,	 normalizing	 the	 signals	 on	
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GAPDH.	In	the	upper	panel,	the	levels	of	three	constant	exons	of	CD44	was	analyzed	and	the	average	
expression	was	calculated	(Average	Exp).	The	signals	of	si-CTRL	cells	were	set	to	1.	In	the	lower	panel,	
the	levels	of	different	variable	exons	of	CD44	were	measured	and	normalized	on	the	Average	Exp	of	
CD44	 in	 si-RALY	cells.	This	allowed	the	quantization	of	alternatively	 spliced	exons	 regardless	of	 the	
absolute	 expression	 of	 the	 whole	 CD44	 gene.	 The	 signals	 of	 si-CTRL	 cells	 were	 set	 to	 1.	 The	
downregulation	 of	 RALY	 increases	 the	 levels	 of	 some	 alternatively	 spliced	 exons	 of	 CD44.	 All	 the	
graphs	of	the	figure	show	the	mean	of	 five	 independent	experiments	±	S.D.	P-value	was	calculated	
using	an	unpaired	two	tailed	t-test	(*P<0.05;	**P<0.01;	***P<0.001)	between	the	si-RALY	values	and	
the	si-CTRL	signals,	which	were	set	to	1.	
Taken	 together,	 these	 results	 suggest	 that	 RALY	 does	 not	 have	 a	 prominent	 role	 in	
splicing,	 since	 its	 downregulation	 did	 not	 affect	 constitutive	 neither	 splicing	 efficiency	
nor	timing	in	different	targets.	However,	upon	RALY	downregulation,	some	effects	were	
observed	 in	 the	 alternative	 splicing	 pattern	 of	CD44	mRNA.	 Further	 experiments	with	
more	sensitive	techniques,	as	for	example	RNA-seq,	could	better	define	the	involvement	
of	RALY	in	alternative	splicing,	giving	a	broad	overlook	on	global	splicing	events	but	also	
allowing	a	specific	focus	on	RALY	target	transcripts.		
	
As	 a	 last	 analysis	 of	 the	 relationship	 between	 RALY	 and	 splicing,	 a	 splicing	 specific	
analysis	was	 performed	on	 the	microarray	 experiment	 previously	 shown	 in	Fig.	 10.	 In	
fact,	 the	 HTA2.0	microarray	 previously	 used	 for	 the	 gene	 expression	 analysis	 allowed	
also	 to	analyze	splicing.	Briefly,	 the	array	used	specific	probe-sets	 targeting	differently	
spliced	exons	to	evaluate	their	abundance,	and	therefore	the	level	of	specific	isoforms,	
inside	the	cells.	The	signal	of	every	probe-set	was	normalized	on	the	cellular	abundance	
of	the	whole	transcript	so	to	avoid	biases	due	to	the	upregulation	or	downregulation	of	
genes	or	 specific	 transcript	 isoforms	upon	RALY	downregulation	 (less	 total	gene	X	and	
less	 exon	 A	 =	 no	 significance,	 no	 changes	 in	 gene	 X	 and	 less	 exon	 A	 =	 differences	 in	
isoforms	 upon	 RALY	 downregulation).	 Compared	 to	 si-CTRL	 cells,	 in	 si-RALY	 cells	 the	
bioinformatics	analysis	detected	as	misregulated	847	cassette	exon	events,	namely	exon	
skipping	or	retention,	254	events	caused	by	alternative	5’	donor	sites,	216	events	caused	
by	alternative	3’	acceptor	sites,	and	65	intron	retention	events	(Fig.	19A	and	Table	4	in	
Appendix).	 Functional	annotation	enrichment	analysis	by	Gene	Ontology	and	pathway	
databases	 identified	 cellular	 localization,	 protein	 localization	 to	 membrane	 and	 cell	
migration	as	biological	processes	significantly	associated	with	the	mis-spliced	transcripts	
upon	RALY	downregulation	(Fig.	19B	and	Table	4	in	Appendix).		
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Figure		19.	Microarray	analysis	of	splicing	upon	RALY	downregulation.	(A)	Barplot	representing	the	
number	of	altered	alternative	 splicing	events	detected	by	microarray	analysis	upon	RALY	 silencing.	
(B)	 Functional	 annotation	 enrichment	 analysis	 of	 altered	 alternative	 splicing	 events	 upon	 RALY	
downregulation.	 The	 bars	 display	 enriched	 classes	 from	 Gene	 Ontology	 terms	 and	 KEGG	 or	
REACTOME	pathways.	The	number	of	DEGs	falling	in	each	category	is	displayed	on	the	right	of	each	
bar.	
To	be	noted,	none	of	the	represented	Gene	Ontology	classes	for	the	alternative	splicing	
analysis	was	detected	as	enriched	in	the	transcriptome	analysis.	This	 is	due	to	the	fact	
that	the	splicing	specific	signal	of	the	microarray	is	normalized	on	the	signal	of	the	entire	
transcript.	 For	 this	 reason,	 the	 detection	 of	 abnormal	 alternative	 splicing	 events	 for	
highly	misregulated	genes	becomes	very	stringent.		
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These	experiments	still	need	to	be	validated,	but	suggest	the	existence	of	a	relationship	
between	 RALY	 and	 constitutive/alternative	 splicing.	 RALY	 was	 shown	 to	 interact	 with	
different	 RBPs	 involved	 in	 the	 co-transcriptional	 processing	 of	 RNAs,	 such	 as	 U2AF2,	
MATR3,	 EIF4A3,	 PRP19	 and	 SR	 proteins	 4,17,122,179–183.	 Future	 experiments	 with	 more	
informative	techniques	will	better	understand	if	RALY	is	involved	in	splicing.		
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6.2	MaDEleNA	
During	 my	 PhD	 I	 contributed	 to	 project	 MaDEleNA	 (Developing	 and	 Studying	 novel	
intelligent	 nanoMaterials	 and	 Devices	 towards	 Adaptive	 Electronics	 and	 Neuroscience	
Applications),	which	aimed	to	advancements	in	the	field	of	adaptive	electronics.		
	
Neuronal	 cells	 can	 organize	 and	 form	highly	 articulated	 networks,	 constituting	 one	 of	
the	most	complex	and	interesting	biological	systems	in	nature.	The	extraordinary	degree	
of	interaction	achieved	by	neuronal	nets	allows	neurons	to	form	“computing	units”	with	
a	 large	 parallel	 processing	 power	 able	 to	 greatly	 overcome	 the	 capacity	 of	 modern	
computing	devices	184.	To	overtake	this	limit,	new	architectures	are	being	investigated.	A	
synapse	is	essentially	a	two-terminal	device	and	bears	striking	functional	resemblance	to	
an	 electrical	 device	 termed	memristor	 (memory	 +	 resistor)	 185.	 Neurons	 modify	 their	
conductive	and	resistive	capacity	depending	on	their	previous	“stimulatory	experience”,	
allowing	the	information	to	proceed	only	when	the	received	stimuli	exceed	the	voltage	
threshold	of	 the	axon	hillock.	The	memristor's	electrical	 resistance	 is	not	constant	but	
depends	on	the	currents	that	have	previously	flowed	through	the	device.	After	a	current	
input,	the	memristor	retains	an	electrical	charge,	establishing	a	dynamic	threshold	that	
will	have	 to	be	surpassed	by	 the	next	 input	 to	make	 the	output	being	 transmitted	 186.	
Processors	 built	 with	 memristors	 will	 vary	 their	 physical	 characteristics	 according	 to	
their	 “experience”,	 progressively	 developing	 features	 such	 as	 learning	 and	 decision	
making	at	the	hardware	level	(at	present,	computer	learning	is	essentially	implemented	
in	 the	software	 level).	As	a	 future	application,	devices	with	 these	characteristics	 could	
potentially	be	able	to	“communicate”	with	neurons	themselves,	sensing	their	electrical	
activity	and	adapting	to	 it.	The	application	of	 these	technology	could	be	endless,	 from	
the	modelling	of	artificial	neural	networks	to	the	construction	of	novel	surgical	devices.	
Given	 the	 dynamicity	 of	memristors	 being	 intrinsic	 in	 their	 constitutive	materials	 and	
given	 the	 rigid	 environmental	 and	 culturing	 conditions	 required	by	neurons,	 our	main	
aim	 have	 been	 to	 test	 the	 bio-	 and	 neuro-compatibility	 of	 different	 substrates	 with	
memristive	electrical	properties.	In	particular,	we	analyzed	the	bio-permissive	properties	
of	Polyaniline	 (PANI)	and	TiO2,	 the	 latter	 in	different	Oxygen	stoichiometric	ratios.	The	
results	are	presented	in	the	Publications	section.	

7. EXPERIMENTAL	PROCEDURES	
Cell	cultures	and	transient	transfections.		
HeLa	cells	and	MCF7	were	grown	 in	DMEM	supplemented	with	10%	FBS	as	previously	
described	 109.	 The	 transfections	 of	 the	 plasmids	 were	 performed	 using	 the	 TransIT	
transfection	 reagent	 (Mirus,	 Bio	 LLC)	 according	 to	 the	 manufacturer’s	 protocols.	 The	
transfections	of	ON-target	plus	SMART-pool	siRNAs	and	control	siRNAs	(Thermo	Fisher)	
were	 performed	 with	 the	 INTERFERin	 transfection	 reagent	 (Polyplus-Transfection),	
according	to	the	manufacturer’s	protocols.	
	
Quantitative	real-time	PCR.		
Total	RNA	was	purified	from	cells	using	the	TRIzol	Reagent	(Thermo	Fischer)	and	retro-
transcribed	 using	 the	 RevertAid	 First	 Strand	 cDNA	 Synthesis	 Kit	 (Thermo	 Fisher).	 The	
KAPA	SYBR	FAST	qPCR	Kit	(KAPA	Biosystems)	was	used	for	the	qRT-PCR.	All	primers	were	
purchased	by	IDT	(TEMA	Ricerca)	and	are	listed	in	the	Appendix,	Table	5.	The	samples	
were	 incubated	 in	the	BioRad	CFX96	Thermo	Cycler	 for	40	cycles	and	the	results	were	
analysed	 with	 the	 Bio-Rad	 CFX	 Manager	 version	 2.1.	 The	 relative	 expression	 was	
calculated	according	to	the	2-∆∆Ct	method.	
	
Constructs.		
RT-PCR	was	performed	on	total	RNA	isolated	from	HeLa	cells	using	the	TRIzol	Reagent.	
Human	RALY	cDNA	was	amplified	with	the	Phusion	High-Fidelity	DNA	polymerase	(New	
England	 BioLabs),	 and	 then	 cloned	 in	 frame	 with	 the	 c-Myc/DDK	 tag	 (pCMV6-Entry	
Vector,	 Origene).	 The	 sequences	 of	 the	 primers	 used	 in	 this	 study	 are	 listed	 in	 the	
Appendix,	Table	5.	
	
Preparation	of	cell	extracts	and	Western	blot	analysis.		
The	 cells	were	washed	with	pre-warmed	PBS,	 lysed	 in	 lysis	 buffer	 [0.1%	Triton	X-100,	
0.5%	 NP-40,	 150	 mM	 NaCl,	 20	 mM	 Tris-HCl	 pH	 8.0,	 plus	 protease	 inhibitor	 mixture	
(Roche),	 including	 1	 mM	 phenylmethylsulfonyl	 fluoride	 (PMSF)].	 Equal	 amounts	 of	
proteins	 were	 separated	 on	 12%	 SDS-PAGE	 and	 blotted	 onto	 nitrocellulose	 (GE	
Healthcare).	Western	blots	were	probed	with	 the	 following	primary	 antibodies:	 rabbit	
	 76	
polyclonal	 anti-RALY	 (A302-070A,	 Bethyl	 Laboratories);	 mouse	 monoclonal	 anti-c-Myc	
(M4439,	 Sigma	 Aldrich),	 rabbit	 polyclonal	 anti-H1X	 (ab31972,	 Abcam),	 mouse	
monoclonal	 anti-Beta	 Tubulin	 (sc-53140,	 Santa	 Cruz	 Biotechnology),	 rabbit	 polyclonal	
anti-H3	 (ab1791,	 Abcam),	 mouse	 monoclonal	 anti-E2F1	 (sc-251,	 Santa	 Cruz	
Biotechnology),	 mouse	 monoclonal	 anti-Ubiquitin	 (3936,	 Cell	 Signaling	 Technology),	
mouse	monoclonal	anti-GAPDH	(sc-32233,	Santa	Cruz	Biotechnology),	rabbit	polyclonal	
anti-FUS/TLS	 (ab2349,	 Abcam).	 Horseradish	 peroxidase	 (HRP)-conjugated	 goat	 anti-
mouse	 and	 anti-rabbit	 antibodies	 (Santa	 Cruz	 Biotechnology)	were	 used	 as	 secondary	
antibodies.	
	
Cell	Fractionation	in	Soluble	and	Chromatin-bound	protein	fractions.	
HeLa	 cells	 were	 resuspended	 in	 radioimmunoprecipitation	 assay	 (RIPA)	 buffer	 with	
protease	inhibitors	and	was	homogenized	with	a	23G	needle.	After	20	min	incubation	on	
ice,	cell	lysates	were	centrifuged	at	1000	×	g	for	10	min	at	4	°C.	The	supernatants	were	
collected	 (soluble	 fraction)	 and	 the	 pellet	 was	 resuspended	 with	 RIPA	 buffer	
supplemented	 with	 0.3%	 SDS	 and	 250	 units/mL	 benzonase.	 Pellet	 suspensions	 were	
incubated	on	 ice	 for	10	min	and	centrifuged	again	at	1000	×	g	 for	10	min	at	4	°C.	The	
supernatant	 from	 the	 second	 centrifugation	 contained	 most	 of	 the	 chromatin-bound	
proteins.		
	
Micrococcal	Nuclease	Cell	Fractionation.		
Cell	fractionation	was	performed	as	described	by	Yang	et	al.	100.	Briefly,	HeLa	cells	were	
washed	 with	 pre-warmed	 PBS	 and	 incubated	 for	 10	 minutes	 on	 ice	 in	 Nucleus	
Separation	Buffer	 (NSB)	 [10	mM	KCl,	 1.5	mM	MgCl2,	 0.34	M	Sucrose,	 10%	Glycerol,	 1	
mM	DTT,	0.1%	Triton	X100]	supplemented	with	Protease	Inhibitors	(Roche)	and	RNase	
Inhibitors	 (NEB)	 depending	 on	 the	 experiment.	 For	 RNase	 treatment,	 RNase	 A	 (100	
µg/ml)	was	added	to	NSB	and	after	the	10	minutes	on	ice,	the	extract	was	incubated	at	
37°C	 for	 10	 minutes.	 The	 samples	 were	 then	 centrifuged	 at	 1400	 x	 g	 at	 4°C	 for	 10	
minutes	to	pellet	the	nuclei.	The	supernatant	(cytosolic	fraction)	was	collected	and	the	
nuclei	 pellet	was	 resuspended	 in	NSB	 supplemented	with	1	mM	CaCl2	 and	2000	U/ml	
Micrococcal	Nuclease	(MNase)	(NEB),	and	incubated	at	37°C	for	10	minutes.	EGTA	was	
afterwards	 added	 to	 arrive	 at	 a	 2	 mM	 concentration	 to	 stop	 MNase	 reaction.	 The	
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samples	were	 centrifuged	 at	 1400	 x	 g	 at	 4°C	 for	 10	minutes	 to	 pellet	 chromatin.	 The	
supernatant	(Nuclear	Soluble	fraction)	was	collected	and	chromatin	was	resuspended	in	
NSB	supplemented	with	150	mM	NaCl.	The	tubes	were	left	in	rotation	at	4°C	for	2	hours.	
The	samples	were	then	centrifuged	at	1400	x	g	at	4°C	for	10	minutes	to	pellet	chromatin	
again.	The	supernatant	was	collected	(Low-Salt	Soluble	fraction,	transcriptionally	active	
chromatin)	and	the	remaining	pellet	was	dissolved	in	NSB	supplemented	with	600	mM	
NaCl.	 The	 samples	 were	 left	 in	 rotation	 at	 4°C	 overnight.	 The	 tubes	 were	 finally	
centrifuged	 at	 1400	 x	 g	 at	 4°C	 for	 10	 minutes	 to	 pellet	 the	 insoluble	 fraction	 of	
chromatin	 and	 the	 last	 supernatant	 was	 collect	 (High-Salt	 Soluble	 fraction,	
transcriptionally	 inactive	 chromatin).	 After	 the	 supernatant	 collections,	 every	 fraction	
was	clarified	with	a	centrifugation	at	16400	x	g	at	4°C	for	2	minutes.	
	
RNA	synthesis	assay.		
HeLa	 cells	were	grown	 for	24	hours	 to	obtain	 a	70-80%	of	 confluence.	 The	 cells	were	
incubated	in	complete	DMEM	supplemented	with	0.5	mM	5-Ethynyluridine	(5EU)	(Jena	
Bioscience)	for	the	desired	amount	of	time.	When	required,	Actinomycin	D	was	added	at	
the	concentration	of	125	ng/ml	at	the	same	moment.		The	cells	were	then	fixed	for	30	
minutes	at	room	temperature	in	fixing	solution	[125	mM	Pipes	pH	6.8,	10	mM	EGTA,	1	
mM	 MgCl2,	 0.2%	 Triton	 X-100,	 3.7%	 formaldehyde].	 Click	 reaction	 with	 5FAM-Azide	
(5FAM)	(Jena	Bioscience)	was	performed	in	staining	solution	[100	mM	Tris	pH	8.5,	1	mM	
CuSO4,	 10mμM	5FAM,	100	mM	ascorbic	 acid	 (in	water)].	 The	 cells	were	washed	 three	
times	 in	 TBS	 supplemented	with	0.5%	Triton	X-100.	 Staining	of	 proteins	was	 achieved	
incubating	 the	 cells	 in	 blocking	 solution	 and	 following	 the	 immunocytochemistry	
protocol	as	described	below.	Further	details	in	Jao	et	al.	124.	
	
Immunocytochemistry	and	fluorescence	microscopy.		
Cells	were	washed	in	pre-warmed	PBS	and	then	fixed	in	4%	PFA	for	15	minutes	at	room	
temperature.	 Immunocytochemistry	 was	 carried	 out	 as	 previously	 described	 109.	 The	
following	primary	antibodies	were	used:	rabbit	polyclonal	anti-RALY	(A302-070A,	Bethyl	
Laboratories);	 mouse	 monoclonal	 anti-c-Myc	 (M4439,	 Sigma	 Aldrich).	 Alexa	 594-	 and	
Alexa	 488-coupled	 goat	 anti-mouse	 and	 anti-rabbit	 IgG	 were	 used	 as	 secondary	
antibodies	 (Santa	 Cruz	 Biotechnology).	 Microscopy	 analysis	 was	 performed	 using	 the	
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Zeiss	Observer	Z.1	microscope	 implemented	with	 the	Zeiss	ApoTome	module.	Pictures	
were	 acquired	 using	 Zen	 Blue	 imaging	 software	 package	 (Zeiss)	 and	 assembled	 with	
Adobe	 Photoshop	 CS6.	 Images	 were	 not	 modified	 other	 than	 adjustments	 of	 levels,	
brightness	and	magnification.	
	
RNA	immunoprecipitation	(RIP).		
RIP	was	performed	as	reported	by	Keene	and	colleagues	with	some	modifications	187.	In	
brief,	4x107	cells	were	grown	in	15	cm-culture	dishes	and	were	irradiated	once	with	150	
mJ/cm2	 at	 254	 nm	using	 an	UVLink	UV-crosslinker	 (Uvitec	 Cambridge).	 The	 cells	were	
lysed	in	lysis	buffer	[10	mM	HEPES	pH	7.4,	100	mM	KCl,	5	mM	MgCl2,	0.5%	NP40,	1mM	
DTT,	100	U/ml	RNase	Out	and	Protease	inhibitor	cocktail	(Roche)]	for	3	hours	at	–	80°C	
and	 centrifuged	 at	 10,000	 x	 g	 for	 20	 min	 at	 4°	 C.	 Then,	 the	 supernatants	 were	 pre-
cleared	 with	 20	 μl	 of	 A/G	 magnetic	 beads	 for	 1hour	 at	 4°C.	 Successively,	 the	
supernatants	were	incubated	for	4	hours	at	4°C	with	protein	A/G	magnetic	beads	coated	
either	with	antibody	anti-RALY	 (A302-069A,	Bethyl	Laboratories)	 (3	μg)	or	with	normal	
rabbit	IgG	polyclonal	antibody	(Millipore).	The	beads	were	then	washed	three	times	with	
NT2	buffer	[50	mM	Tris-HCl	pH	7.5,	300	mM	NaCl,	1	mM	MgCl2,	0.05%	NP-40,	1	%	Urea].	
Each	wash	was	 performed	 on	 a	 rotating	wheel,	 for	 10	minutes,	 at	 4°C.	 The	 RNA	was	
isolated	with	TRIzol	and	processed	for	qRT-PCR	analysis	as	described	below.	The	primers	
used	for	the	qRT-PCR	analysis	are	shown	in	the	Appendix,	Table	5.	
	
RNA	pull-down.		
RNA	pull-down	was	performed	as	previously	described	109.	Briefly,	wild-type	or	mutant	
probes	 (50	 pmol)	 were	 incubated	 with	 30	 μl	 of	 streptavidin-coupled	 Dynabeads	
(ThermoFisher)	for	20	min	at	room	temperature	in	RNA	Capture	Buffer	[20	mM	Tris	(pH	
7.5),	1	M	NaCl,	1	mM	EDTA	20	mM	Tris	(pH	7.5)].	HeLa	cells	were	washed	with	PBS	and	
then	lysed	with	the	lysis	buffer	[20	mM	Tris	(pH	7.5),	50	mM	NaCl,	2	mM	MgCl2,	0.1%	
Tween-20].	The	lysate	(300	μg)	was	incubated	with	biotinylated	RNA	probes	coupled	to	
streptavidin	Dynabeads	for	1	hour	at	4°C	under	rotation.	Dynabeads	were	then	washed	
three	times	with	washing	solution	[20	mM	Tris	(pH	7.5),	15	mM	NaCl,	0.1%	Tween-20],	
solubilized	in	Laemmli	reducing	buffer	and	boiled	for	Western	blot	analysis.	
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RNA	Polymerase	II	Elongation	Rate	and	Splicing	Speed	Analyses.		
RNA	Polymerase	II	elongation	was	monitored	according	to	Singh	and	Padgett	134.	Briefly,	
HeLa	 cells	 were	 grown	 in	 6-well	 plates	 till	 70%	 of	 confluence	 and	 were	 successively	
transfected	 with	 either	 si-CTRL	 or	 si-RALY	 siRNAs.	 After	 72	 hours,	 the	 cells	 were	
incubated	 for	 3	 hours	 in	 complete	 DMEM	 +	 100	 μM	DRB	 to	 block	 RNAPII-dependent	
transcription.	The	cells	were	successively	washed	twice	with	ice-cold	PBS	and	incubated	
with	DMEM	at	37	°C	to	re-activate	transcription.	Cells	were	afterwards	lysed	at	5	minute	
intervals	using	the	lysis	buffer	of	the	High	Pure	Isolation	Kit	(Roche)	and	total	RNA	was	
extracted.	 Reverse	 transcription	 was	 performed	 using	 the	 ImProm-II	 Reverse	
Transcription	 System	 (Promega).	 The	 analysis	 of	 pre-mRNA	 levels	 was	 done	 by	
quantitative	Real-Time	PCR	using	 the	primers	 listed	 in	 the	Appendix,	 Table	 5.	 For	 the	
analysis,	 the	 qRT-PCR	 results	 of	 transfected	 cells	 (si-CTRL	 or	 si-RALY)	 not	 treated	with	
DRB	were	used	as	reference	values	for	the	normalization	of	the	transfected	cells	treated	
with	DRB	for	3	hours	and	allowed	afterwards	to	recover	transcription.	
	
Real-Time	Cell	Analysis.	
The	 cell	 proliferation	 assay	 with	 the	 xCELLigence	 system	 (Roche)	 was	 performed	
according	 to	 the	 manufacturer.	 Briefly,	 5x104	 cells	 were	 seeded	 into	 each	 well	 of	 a	
specific	xCELLigence	E-plate.	Cell	proliferation	was	monitored	by	the	instrument	through	
the	 measurement	 of	 the	 impedance	 of	 the	 bottom	 of	 the	 wells	 for	 three	 days	 with	
detections	 every	 15	minutes.	 The	proliferation	 signals	were	normalized	on	 the	 signals	
acquired	 at	 10	 hours	 post	 seeding,	 so	 to	 normalize	 on	 the	 number	 of	 effectively	
proliferating	cells	in	each	well.		
	
Cell	Cycle	Distribution	Analysis.	
Cell	Cycle	distribution	was	analyzed	as	described	by	Massey	and	colleagues	156.	Briefly,	
104	 cells	 were	 seeded	 into	 a	 96	 well	 plate	 and	 grown	 for	 24	 hours.	 Cells	 were	
successively	 incubated	 in	 DMEM	 plus	 10	 μM	 5-Ethynyl-deoxiuridine	 (5EdU)	 and	
successively	 treated	 for	 Click-it	 reaction	 as	 described	 above.	 Processed	 cells	 were	
successively	analyzed	with	 the	High	Content	 Imaging	System	Operetta	as	described	by	
Massey	and	colleagues	156.		
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High	content	analysis.		
HeLa	cells	were	plated	(1x104	cells/well)	in	96-well	plates	(Corning)	and	transfected	the	
day	 after	 with	 either	 si-CTRL	 or	 si-RALY	 siRNAs	 for	 72	 hours.	 Then	 the	 cells	 were	
incubated	 for	 different	 amounts	 of	 time	 with	 5EU	 0.5	 mM	 in	 warm	 DMEM	 to	 mark	
newly	 synthesized	 RNA	 and	 stained	 with	 5FAM	 through	 Click	 reaction	 (see	 the	 RNA	
synthesis	 assay	 paragraph);	 successively,	 they	 were	 processed	 for	
immunocytochemistry,	starting	from	the	blocking	step	(see	above).	Plates	were	imaged	
on	the	High	Content	Imaging	System	Operetta™	(PerkinElmer).	In	each	of	the	4	wells	for	
every	 condition,	 images	were	acquired	 in	5	preselected	 fields	with	 LWD	20x	objective	
over	three	channels,	with	λ=	380	nm	excitation/λ=	445	nm	emission	for	DAPI,	λ=	495	nm	
excitation/λ=	 519	 nm	 emission	 for	 Alexa	 Fluor	 488	 or	 5FAM,	 with	 λ=	 535	 nm	
excitation/λ=	615	nm	emission	 for	Alexa	Fluor	594.	 For	 feature	extraction,	 the	 images	
were	 analyzed	 by	 Harmony	 software	 version	 4.1	 (PerkinElmer).	 Briefly,	 individual	 cell	
nuclei	were	segmented	based	on	DAPI	staining.	For	the	Click-it	experiment	 (Fig.	4)	 the	
Select	Population	algorithm	allowed	to	 identify	the	sub-population	of	silenced	cells	 for	
RALY	 by	 setting	 a	 fluorescence	 intensity	 threshold	 on	 the	 Alexa	 Fluor	 594	 signal.	 The	
5FAM	signal	was	then	measured	only	in	the	cells	evaluated	as	silenced	for	RALY.	
	
Microarray	Analysis.		
HeLa	 cells	 were	 transfected	 for	 72	 hours	 with	 either	 si-CTRL	 or	 si-RALY	 siRNAs	 as	
described	above,	and	total	RNA	was	extracted	using	the	High	Pure	Isolation	Kit	(Roche).	
Samples	were	prepared	for	hybridization	following	the	Affymetrix	WT	PLUS	Reagent	Kit	
protocol	
(http://www.affymetrix.com/estore/catalog/prod770005/AFFY/WT+PLUS+Reagent+Kit#
1_1).	 The	 amplified	 and	 labeled	 samples	were	 hybridized	 to	 the	 Affymetrix	 GeneChip	
Human	Transcriptome	Array	2.0	(Affymetrix,	Santa	Clara,	CA,	USA).	Arrays	were	washed	
and	 stained	 using	 the	 Affymetrix	 Fluidics	 Station	 450,	 and	 scanned	 in	 the	 Affymetrix	
GeneArray	3000	7G	scanner.	The	experiment	was	performed	in	biological	triplicate.	
The	 CEL	 files	 resulting	 from	 the	 GeneChip	 analysis	 were	 analysed	 with	 affymetrix	
Transcriptome	Analysis	Console	 (TAC)	3.1	and	the	Bioconductor	 library	of	biostatistical	
packages	(http://www.bioconductor.org/).	Raw	data	were	preprocessed	and	normalized	
with	 the	 Robust	 Multichip	 Analysis	 (RMA)	 method.	 Gene	 average	 intensities	 were	
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determined	 with	 the	 Tukey's	 Bi-weight	 Average	 Algorithm,	 using	 Affymetrix	 default	
analysis	 settings.	 Differentially	 expressed	 genes	 (DEGs)	 upon	 RALY	 silencing	 were	
determined	adopting	a	double	threshold	based	on	statistical	significance	(unpaired	One-
Way	ANOVA	FDR	<	0.05)	and	log2	fold	change	(>	0.5	for	up-regulated,	<	-0.5	for	down-
regulated	genes).		
Frequencies	of	RALY	RIP-seq	targets	among	DEGs	were	tested	with	the	“Test	of	Equal	or	
Given	 Proportions”	 implemented	 in	 R.	 The	 ClusterProfiler	 package	 was	 used	 for	
enrichment	 analysis	 of	 DEGs	 lists,	 using	 annotations	 from	 Gene	 Ontology	
(http://www.thegeneontology.org),	 KEGG	 (http://www.genome.jp/kegg/),	 REACTOME	
(http://www.reactome.org/)	 databases.	 The	 significance	 of	 overrepresentation	 was	
determined	 using	 a	 FDR	 threshold	 of	 0.05.	 Gene	 Set	 Enrichment	 Analysis	 (GSEA)	was	
performed	 on	 ranked	 DEGs	 against	 the	 the	 Molecular	 Signatures	 Database	 (MSigDB)	
“Hallmark”	collection	of	annotated	gene	sets	(v	5.2)	188.	
	
Alternative	 Splicing	 analysis	 was	 performed	 with	 Affymetrix	 Transcriptome	 Analysis	
Console	(TAC)	3.1,	using	default	parameters.		Significant	alternative	splicing	events	upon	
RALY	 silencing	 were	 filtered	 using	 the	 following	 criteria:	 absolute	 Splicing	 Index	 >	 2,	
absolute	Splicing	Index	>	1.75	*	absolute	gene	fold	change,	splicing	One-Way	ANOVA	p-
value	<	0.05,	Splicing	Event	Score	>	0.1.	
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9. Appendix	
Table	2,	containing	the	results	of	the	Gene	Expression	analysis	performed	by	microarray	
in	HeLa	cells	where	RALY	was	downregulated,	can	be	consulted	HERE1.		
	
Table	3,	containing	the	results	of	the	Gene	Ontology	and	pathway	analysis	of	the	gene	
expression	part	of	the	microarray	experiment,	can	be	consulted	HERE2.	
	
Table	4,	containing	the	results	of	the	Gene	Ontology	and	pathway	analysis	of	the	splicing	
part	of	the	microarray	experiment,	can	be	consulted	HERE3.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
1:	https://drive.google.com/file/d/0Bwr0nDDQwOP2dWtTNHQxYWh5Nk0/view?usp=sharing	
2:	https://drive.google.com/file/d/0Bwr0nDDQwOP2S0h3bjVva3N5UW8/view?usp=sharing	
3:	https://drive.google.com/file/d/0Bwr0nDDQwOP2OExSSFBSVWthLXc/view?usp=sharing	
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TABLE	5.		List	of	oligonucleotides	used	in	this	study.	
List	of	primers	used	to	clone	RALY	fragments	into	the	pCMV6-Entry	vector	(Origene)	
PRIMER	 SEQUENCE	
RALY-c-Myc		
1-306	Forward	
5’-GCTAGCATGTCCTTGAAGCTTCAGGC	
RALY-c-Myc		
1-306	Reverse	
5’-GCGGCCGCGTCTGCAAGG	
RALY-c-Myc			
1-225	Forward	
5’-GCTAGCATGTCCTTGAAGCTTCAGGC	
	
RALY-c-Myc			
1-225	Reverse	
5’-GCGGCCGCGTACCCTTCTTC	
	
RALY-c-Myc			
143-306	Forward	
5’-GCTAGCATGCCTGTGAAGCGACCCCG	
RALY-c-Myc			
143-306	Reverse	
5’-GCGGCCGCGTCTGCAAGGCC	
RALY-c-Myc			
226-306	Forward	
5’-GCTAGCATGGATGGAGGTGGCGCCG	
	
RALY-c-Myc			
226-306	Reverse	
5’-GCGGCCGCGTCTGCAAGGCC	
	
	
List	of	the	ds-DNA	Cas9	guides	targeting	RALY	cloned	into	the	PX330	vector.	
Crispr/Cas9	
Guide	1	-	exon	1	
5’-	CACCGATCAACTCTCGAGTCTTCAT	
5’-	AAACATGAAGACTCGAGAGTTGATC	
Crispr/Cas9	
Guide	2	-	exon	1	
5’-	CACCGTGGAAACCTCAACACAGCTC	
5’-	AAACGAGCTGTGTTGAGGTTTCCAC	
Crispr/Cas9	
Guide	3	-	exon	1	
5’-	CACCGGCCGGCTGTTCTGTGCACA	
5’-	AAACTGTGCACAGAACAGCCGGCC	
Crispr/Cas9	
Guide	4	-	exon	1	
5’-	CACCGACGGCCATACTTAGAGAAGA	
5’-	AAACTCTTCTCTAAGTATGGCCGTC	
Crispr/Cas9	
Guide	5	-	exon	2	
5’-CACCGCCTAAGCCTGACAGACCCA	
5’-	AAACTGGGTCTGTCAGGCTTAGGC	
	
List	of	the	primers	used	for	the	array	validation	and	for	the	RNAPII	elongation	rate	
measurement.		
Gene	Name	 Assay	Name/Primers	
ACTB	 Hs.PT.56a.40703009	
B2M	 Hs.PT.58v.18759587	
GAPDH	 Hs.PT.39a.22214836	
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RALY	 Hs.PT.58.26374068	
E2F1	
	
FW	5’-GCCAAGAAGTCCAAGAACCA	
RV	5’-CAGTGTCCTCGGAGAGCAG	
OPA1	 FW	5’-TGGAGATCAGAGTGCTGGAA	
RV	5’-AAATAGGGCCACATGGTGAG	
ITPR1	
	
FW	5’-GCTACTCTGCCCAAAAGCAG	
RV	5’-ATTACGGTCCCCAGCAATTT	
CTNNBL1	
	
FW	5’-TGCTGTACAGTCGCTTCTCG	
RV	5’-TGAGCACTTCTGCTCCCTCT	
CCNE1	 FW	5’-AAGTTGCACCAGTTTGCGTA	
RV	5’-AGGGGACTTAAACGCCACTT	
CCNE2	 FW	5’-	TCCTTCACCTTTGCCTGATT	
RV	5’-	CCTCATCTGTGGTTCCAAGTC	
CCNB1	 FW	5’-AGATGGAGCTGATCCAAACC	
RV	5’-TGGCTCTCATGTTTCCAGTG	
CCNB2	 FW	5’-GGCTGGTACAAGTCCACTCC	
RV	5’-ACTTGGAAGCCAAGAGCAGA	
CDK1	 FW	5’-CCCTCCTGGTCAGTACATGG	
RV	5’-TCATCAATCAAGAGATTTTGAGG	
CDC25A	 FW	5’-AGCCTCTGGACAGCTCCTCT	
RV	5’-CTTCAACACTGACCGAGTGC	
CCNT1	 FW	5’-	TGGGAGATCCCAGTCTCAAC	
RV	5’-	CCTGTTGGGAGTTTTCTCCA	
GTF2A1	 FW	5’-GCGAACTCGGCAAATACAAA	
RV	5’-TTCATCCACTCCATCATCCA	
GTF2E2	 FW	5’-GATTCCATGGACGAGGAGAA	
RV	5’-ACTCCAGCCAAGTGTTCGTT	
ELL2	 FW	5’-CCATACAGGGACAGGGTGAT	
RV	5’-CAGGCCAGTCTCTTTGAAGC	
SUPT16H	 FW	5’-ATAACGCTGTCATGGACGTG	
RV	5’-CTAGGGAGCCTTCACGGAAT	
SSRP1	 FW	5’-TTGTCAACTTTGCTCGTGGT	
RV	5’-TTTTCGCGTTGACAAAATCA	
TFDP1	 FW	5’-GGGACCACTTCCTACAACGA	
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RV	5’-CTGACATTCCTGAGCCGAGT	
ITPR1	Ex5-In5	 FW	5’-AGTTCTGGAAAGCCGCTAAGCC	
RV	5’-ACCAAGGCAGCCACTCACTACT	
ITPR1	Ex4-In4	 FW	5’-CCTGGTTGATGATCGTTGTGTT	
RV	5’-TACTCCAGGAAAGCCACCACCTTA	
ITPR1	Ex3-In3	 FW	5’-TGTACGCGGAGGGATCGACAAA	
RV	5’-CAACCGCACTTAGAAAGCCAAG	
ITPR1	Ex27-In27	 FW	5’-AGAGCTTTGGGTGTACAAAGGGCA	
RV	5’-AGTTTCGAGAAGCCCATCCATCCA	
OPA1	In28-Ex29	 FW	5’-CCCTGACCTCAGTTTGTTAAATGGG	
RV	5’-CAGCTGATGGTTAAAGCGCCCGTA	
CTNNBL1	Ex5-In5	 FW	5’-TGAAGAGGGAGCAGAAGTGCTCAT	
RV	5’-TATTCACTCCAGCCTCACCACACT	
	
List	of	the	primers	used	for	the	splicing	measurements.		
KIT1	–	Ex1-In1	
	
FW	5’-	TGCGTTCTGCTCCTACT	
RV	5’-	GTCCTCTCTCCGGATGC	
KIT1	–	In2		 RV	5’-	CTCAGTCATCCATATGTCATCC	
LRP1B	–	Ex2-In2	 FW	5’-	CTGACTGCCCTGATGATTC	
RV	5’-	AACAGCAGTCATCTGTGAAA	
LRP1B	–	In3	 RV	5’-	ATTTCAGTTGCATTGTTCCAC	
ASCC2	–	Ex2-In2	 FW	5’-	ACAAGGACCCGAAGACA	
RV	5’-	GGAACAGATAAAGACGGAATTTAC	
ASCC2	–	In3	 RV	5’-TGGCATGTCATGTGCTTT		
CDK6	–	Ex2-In2	 FW	5’-	CTGGAGACCTTCGAGCA		
RV	5’-	TTTCTGGGCCTGAGGATT	
CDK6	–	In3	 RV	5’-	CTATAATAGTCGACTGCCTGATAA	
GSTA4	–	Ex4-In4	 FW	5’-	CTCTTTGGCAAGAACCTCAA	
RV	5’-	AGTAAATGTGGTGTGCTACAG		
GSTA4	–	In5	 RV	5’-	GTTTGTGGCAGCTTCTTTG	
EVI5	–	Ex14-In14	 FW	5’-	AGACAGCAAGTCAAGGATTTAG	
RV	5’-	GGTCATCAGGTACTTCAAACTC	
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EVI5	–	In15	 RV	5’-	CTAGGGATGATACAATCTGTGC	
DLEU2	–	Ex1-In1	 FW	5’-	GAGCCCAGAGCTCCGAT	
RV	5’-	GAAAGCCCACAGTGTTGAAAG	
DLEU2	–	In2	 RV	5’-	CTAGTCCGATTATATTGCAAAGACA	
NPLOC4	–	Ex11-In11	 FW	5’-	CCAGAACAAGCATCCCAA	
RV	5’-	ACGAGGTGGTAATATTTACAGT	
NPLOC4	–	In12	 RV	5’-	CCATTCTCCATGTACAGAGTTC		
CTNNBL1	–	Ex1-In1	 FW	5’-	GGCGAACTTCTGAGCTACCA	
RV	5’-	GTGAGATGAAAGGGCTCTGG	
CTNNBL1	–	Ex2-In2	 FW	5’-	ATGGGGAAGAGGAAGAGGAA	
RV	5’-	GATGGGAAGCTCAGACAAGC	
CTNNBL1	–	Ex3-In3	 FW	5’-	GAGCCATTGGATGAAAGCTC	
RV	5’-	AAACGCCACAGAGGAGACAT	
CTNNBL1	–	In4	 RV	5’-	GGAGAAAGAGTAACAGCACTTCCC	
ITPR1	–	Ex3-In3	 FW	5’-TGTACGCGGAGGGATCGACAAA	
RV	5’-CAACCGCACTTAGAAAGCCAAG	
ITPR1	–	In4	 RV	5’-TACTCCAGGAAAGCCACCACCTTA	
ITPR1	–	Ex5-In5	 FW	5’-AGTTCTGGAAAGCCGCTAAGCC	
RV	5’-ACCAAGGCAGCCACTCACTACT	
ITPR1	–	In6	 RV	5’-	TCACGCTGAGAGATGACCAG	
Thoc2	–	Ex36-In36	 FW	5’-	GGCAAAGAAAAAGGCAGTGA	
RV	5’-	CAATACCTCTTCTTCCCACTCC	
Thoc2	–	In37	 RV	5’-	TCAGCCCTTAAGCATATAAACCA	
Thoc2	–	Ex38-In38	 FW	5’-	GTCCTCGGACAAGCACAGAT	
RV	5’-	ACCCGAAGACTTGGTCGTTA	
Thoc2	–	In39	 	 RV	5’-	TACACTGGTAGAATTCGGCAGAT	
CTNNBL1	–	Ex4-In4	 FW	5’-	TACCACCTTCTGGTGGAGCTGAAT	
RV	5’-	GGAGAAAGAGTAACAGCACTTCCC	
CTNNBL1	–	In5	 RV	5’-	TATTCACTCCAGCCTCACCACACT	
Thoc2	–	Ex37-In37	 FW	5’-	GAAACGGGACAGTTCAGGAG	
RV	5’-	TCAGCCCTTAAGCATATAAACCA	
  105 
Thoc2	–	In38	 	 RV	5’-	ACCCGAAGACTTGGTCGTTA	
ATXN10	–	Ex10-In10	 FW	5’-	TTGATCCTGGACAACTGCAA	
RV	5’-	CATGAGGCAAGGGACTTGTT	
ATXN10	–	In11	 RV	5’-	GCATAAAGCCGGAACAAAAA	
MAPK8	–	Ex6-In6	 FW	5’-	GGCTACAAGGAAAACGGTCA	
RV	5’-	ATAAGGGCCCCAAGTTTTTC	
MAPK8	–	In7	 RV	5’-	ACAATTGAGCAGGGTTCAGA	
	
RNA	probes	used	in	the	RNA	pull-down	experiment:	
	
WT	E2F1	3’UTR	poly-U	 AAAGGUUUUUUCUGAU	
Mutated	E2F1	3’UTR	poly-U	 AAAGGUCUCUCCUGAU	
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